[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 387
1. Terzi A, Saglam EA, Barak A, Soylemezoglu F: The significance of immunohistochemical expression of Ki-67, p53, p21, and p16 in meningiomas tissue arrays. Pathol Res Pract; 2008;204(5):305-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The significance of immunohistochemical expression of Ki-67, p53, p21, and p16 in meningiomas tissue arrays.
  • Although histologic grading of meningiomas has prognostic and clinical implications, it is difficult in some cases to predict the outcome of patients.
  • There have been several efforts to evaluate the use of different immunohistochemical markers for predicting meningioma prognosis.
  • We analyzed the immunohistochemical expression of Ki-67, p53, p21, p16, and PTEN proteins in 130 meningiomas (64 benign, 39 atypical, and 27 malignant meningiomas) using tissue microarray.
  • There was a statistically significant correlation between the expression of Ki-67, p53, p21, p16, and the grade of meningiomas (p0.001).
  • By ordinal logistic regression, p53 and Ki-67 were significantly associated with grade, and an increase of 1% in the labeling index of these markers resulted in an increase in the risk of raising the grade by 2.17 and 1.49, respectively.
  • Histological grade, p53, Ki-67 labeling indices, and overexpression of p16 were strongly associated with decreased event-free survival in univariate analysis.
  • In contrast, multivariate analysis revealed that only tumor grade is an independent factor for predicting meningioma recurrence.
  • We conclude that the Ki-67 and p53 labeling indices are useful additional tools in discriminating atypical from benign or anaplastic meningiomas, especially in histological borderline cases.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p16 / analysis. Cyclin-Dependent Kinase Inhibitor p21 / analysis. Immunohistochemistry. Ki-67 Antigen / analysis. Meningeal Neoplasms / chemistry. Meningioma / chemistry. Tissue Array Analysis. Tumor Suppressor Protein p53 / analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18374497.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Ki-67 Antigen; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


2. Riemenschneider MJ, Perry A, Reifenberger G: Histological classification and molecular genetics of meningiomas. Lancet Neurol; 2006 Dec;5(12):1045-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological classification and molecular genetics of meningiomas.
  • Meningiomas account for up to 30% of all primary intracranial tumours.
  • They are histologically classified according to the World Health Organization (WHO) classification of tumours of the nervous system.
  • Most meningiomas are benign lesions of WHO grade I, whereas some meningioma variants correspond with WHO grades II and III and are associated with a higher risk of recurrence and shorter survival times.
  • Mutations in the NF2 gene and loss of chromosome 22q are the most common genetic alterations associated with the initiation of meningiomas.
  • With increase in tumour grade, additional progression-associated molecular aberrations can be found; however, most of the relevant genes are yet to be identified.
  • High-throughput techniques of global genome and transcriptome analyses and new meningioma models provide increasing insight into meningioma biology and will help to identify common pathogenic pathways that may be targeted by new therapeutic approaches.
  • [MeSH-major] Meningeal Neoplasms / classification. Meningioma / classification. Molecular Biology / methods

  • COS Scholar Universe. author profiles.
  • SciCrunch. KEGG: Data: Disease Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Lancet Neurol. 2007 Feb;6(2):105
  • (PMID = 17110285.001).
  • [ISSN] 1474-4422
  • [Journal-full-title] The Lancet. Neurology
  • [ISO-abbreviation] Lancet Neurol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 116
  •  go-up   go-down


3. Petridis AK, Doukas A, Mahvash M, Dörner L, Hugo HH, Mehdorn HM: A case of rapid-growing anaplastic meningiomas. BMJ Case Rep; 2009;2009
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of rapid-growing anaplastic meningiomas.
  • Meningiomas are tumours originating from the leptomeningeal covering of the brain and spinal cord and are generally benign and slow growing.
  • Such factors are histopathological ones, such as necrosis and hypercellularity, the World Health Organization (WHO) grade, mitotic index, positivity of proliferation markers (Ki-67 or MIB-1), clinical parameters such as age, gender, localisation, cytogenetic factors and radiation treatment.
  • The present case reports a patient with a giant meningioma over the right frontal lobe who had almost all possible negative prognostic parameters and showed an explosive multifocal recurrence in a timespan of about 5 months.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Neurol. 1986 Mar;25(3):233-42 [3945904.001]
  • [Cites] Neurochirurgie. 1986;32(2):135-9 [3724943.001]
  • [Cites] Pediatr Neurosurg. 2008;44(2):153-8 [18230932.001]
  • [Cites] Virchows Arch. 2006 Nov;449(5):529-38 [17016718.001]
  • [Cites] Br J Neurosurg. 2004 Dec;18(6):617-21 [15799195.001]
  • [Cites] Orbit. 2008;27(4):321-3 [18716974.001]
  • [Cites] Neurosurg Focus. 2008;24(5):E7 [18447746.001]
  • (PMID = 21852998.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3030266
  •  go-up   go-down


Advertisement
4. Mosqueda-Taylor A, Domínguez-Malagon H, Cano-Valdez AM, Montiel-Hernandez AM: Primary extracranial meningioma of the mandible. Med Oral Patol Oral Cir Bucal; 2009 Apr;14(4):E167-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary extracranial meningioma of the mandible.
  • Meningiomas are benign tumors of mesodermal origin that arise from arachnoid cell clusters that penetrate the dura to form arachnoid villi.
  • Extracranial meningiomas (EM) comprise only 2% of all meningiomas, and only six cases of primary EM of the jawbones have been described to date.
  • They may arise as an extension of intracranial meningiomas or as primary tumors and may be clinically indistinguishable from other benign tumours of the jaws, as they usually present as a well-delineated unencapsulated tumors.
  • [MeSH-major] Mandibular Neoplasms. Meningioma

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19333184.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 16
  •  go-up   go-down


5. Sayagués JM, Tabernero MD, Maíllo A, Trelles O, Espinosa AB, Sarasquete ME, Merino M, Rasillo A, Vera JF, Santos-Briz A, de Alava E, Garcia-Macias MC, Orfao A: Microarray-based analysis of spinal versus intracranial meningiomas: different clinical, biological, and genetic characteristics associated with distinct patterns of gene expression. J Neuropathol Exp Neurol; 2006 May;65(5):445-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microarray-based analysis of spinal versus intracranial meningiomas: different clinical, biological, and genetic characteristics associated with distinct patterns of gene expression.
  • It has long been recognized that spinal meningiomas show particular clinical and histological features.
  • Here, we compare the clinico-biological characteristics as well as the genetic abnormalities and patterns of gene expression of spinal and intracranial meningiomas.
  • Fourteen spinal and 141 intracranial meningioma patients were analyzed at diagnosis.
  • Additionally, microarray analyses were performed on a subgroup of 18 histologically benign meningiomas (7 spinal and 11 intracranial).
  • Upon comparison with intracranial tumors, spinal meningiomas showed a marked predominance of psammomatous and transitional tumors (p = 0.001), together with a higher proportion of cases displaying a single tumor cell clone by iFISH (p = 0.004).
  • Analysis of gene expression profiles showed differential expression between spinal and intracranial meningiomas for a total of 1555 genes, 35 of which allowed a clear distinction between both tumor types.
  • In summary, we show the occurrence of unique patterns of genetic abnormalities and gene expression profiles in spinal as compared to intracranial meningiomas that provide new insights into the molecular pathways involved in the tumorigenesis and progression of spinal meningiomas, and could help explain their particular clinical and histological features.
  • [MeSH-major] Gene Expression / physiology. Meningeal Neoplasms / genetics. Meningioma / genetics. Oligonucleotide Array Sequence Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16772868.001).
  • [ISSN] 0022-3069
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger
  •  go-up   go-down


6. Mazzoni A: The petro-occipital trans-sigmoid approach for lesions of the jugular foramen. Skull Base; 2009 Jan;19(1):48-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A retrospective review was conducted of 61 patients with jugular fossa tumors that included lower cranial nerve schwannomas, paragangliomas, meningiomas, chordomas, cholesteatomas, and other benign or low-grade malignant tumors.
  • Good outcomes were achieved for schwannomas, meningiomas, chondrosarcomas, and papillary adenoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Skull Base Surg. 1995;5(3):157-67 [17170942.001]
  • [Cites] Arch Otolaryngol. 1964 Mar;79:219-24 [14090421.001]
  • [Cites] J Laryngol Otol. 1952 Jul;66(7):302-14 [14938784.001]
  • [Cites] Arch Otolaryngol. 1971 Mar;93(3):227-31 [5100624.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1982 Sep-Oct;91(5 Pt 1):474-9 [6291440.001]
  • [Cites] Laryngoscope. 1974 Nov;84(11):2006-32 [4373628.001]
  • [Cites] J Neurosurg. 1971 Jul;35(1):59-64 [4328295.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1997 May;106(5):370-9 [9153100.001]
  • (PMID = 19568342.001).
  • [ISSN] 1531-5010
  • [Journal-full-title] Skull base : official journal of North American Skull Base Society ... [et al.]
  • [ISO-abbreviation] Skull Base
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2637570
  • [Keywords] NOTNLM ; Jugular foramen / petro-occipital trans-sigmoid approach / surgical procedures / tumors of jugular foramen
  •  go-up   go-down


7. Vankalakunti M, Vasishta RK, Das Radotra B, Khosla VK: MIB-1 immunolabeling: a valuable marker in prediction of benign recurring meningiomas. Neuropathology; 2007 Oct;27(5):407-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MIB-1 immunolabeling: a valuable marker in prediction of benign recurring meningiomas.
  • Histological analysis has limited value to predict biological behavior of meningiomas.
  • We investigated the utility of cell proliferative indicator in the evaluation of histologically benign meningiomas.
  • We selected 25 benign non-recurrent meningiomas, 15 benign recurrent meningiomas after complete surgical resection, 30 atypical meningiomas, and 15 anaplastic meningiomas out of 384 cases studied.
  • There was no dependable histological parameter to predict recurrence among benign-looking meningiomas.
  • The mean MIB-1 HLI values +/- SD were 3.47 +/- 2.0% for benign meningiomas, 5.08 +/- 4.0% for atypical meningiomas and 11.66 +/- 7.06% for anaplastic meningiomas.
  • In comparison, the mean MIB-1 HLI of benign non-recurrent meningiomas were 2.66 +/- 1.7% and with recurrence were 4.21 +/- 2.78% (P = 0.0339).
  • Using receiver operating characteristic, it was seen that neoplasm recurred with the MIB-1 HLI of > 2.6 having the sensitivity of 64.6% and specificity of 68% among benign (grade I) meningiomas.
  • MIB-1 HLI, integrated with standard histopathology can provide better information about the disease biological nature in benign meningiomas.
  • [MeSH-major] Biomarkers / analysis. Ki-67 Antigen / analysis. Meningeal Neoplasms / pathology. Meningioma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18018472.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Ki-67 Antigen
  •  go-up   go-down


8. Setzer M, Vatter H, Marquardt G, Seifert V, Vrionis FD: Management of spinal meningiomas: surgical results and a review of the literature. Neurosurg Focus; 2007;23(4):E14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of spinal meningiomas: surgical results and a review of the literature.
  • OBJECT: In this report, the authors describe their experience in the surgical management of spinal meningiomas at two neurosurgical centers.
  • METHODS: Eighty consecutive patients (22 men and 58 women) with spinal meningiomas who had undergone an operation at two specific neurosurgical centers were included in this study.
  • A review of the literature yielded an additional 651 patients with spinal meningiomas from 9 large studies.
  • The Cox proportional hazards regression analysis showed three significant predictor variables for recurrence: invasion of the arachnoid/pia (p < 0.05; hazard ratio [HR] 1.8, 95% CI 1.2-3.6), Simpson resection grade (p < 0.012, HR 6.8, 95% CI 1.5-3.0), and histological tumor grade (Grade I; p < 0.001, HR 0.001-0.17).
  • CONCLUSIONS: Because of the excellent outcome of surgery for benign spinal meningiomas and the association between duration of symptoms and neurological compromise with a poor functional outcome, early operation is the treatment of choice.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Spinal Cord Neoplasms / surgery

  • COS Scholar Universe. author profiles.
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961038.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 45
  •  go-up   go-down


9. Sioka C, Kyritsis AP: Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas. J Neurooncol; 2009 Mar;92(1):1-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas.
  • Meningioma is a common intracranial tumor, originating from the meninges of the skull or spinal canal.
  • Most meningiomas are benign tumors, however atypical or anaplastic tumors can be found in 6% of cases.
  • Patients with asymptomatic small benign meningiomas can be followed without therapy, but in symptomatic patients complete surgical resection should be performed.
  • Antiprogesterone treatment can also be considered in recurrent benign meningiomas.
  • Immunotherapy with interferon-alpha and chemotherapy should be reserved for all cases of recurrent meningiomas (benign, atypical, and malignant) when all the standard therapies have failed or contraindicated.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Immunotherapy / methods. Meningeal Neoplasms / therapy. Meningioma / therapy. Neoplasm Recurrence, Local / therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2004 Jun;68(2):131-40 [15218949.001]
  • [Cites] J Neurosurg. 1997 May;86(5):840-4 [9126900.001]
  • [Cites] Cancer. 2007 Feb 1;109(3):588-97 [17177201.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):271-5 [9007858.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Mar;74(3):543-7 [1346787.001]
  • [Cites] Rev Neurol. 1997 Dec;25(148):2002-5 [9528047.001]
  • [Cites] Clin Neuropathol. 2004 Jan-Feb;23(1):21-7 [14986930.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1992 Jun;55(6):486-90 [1619417.001]
  • [Cites] J Neurosurg. 2005 Sep;103(3):508-17 [16235684.001]
  • [Cites] Br J Neurosurg. 2004 Oct;18(5):495-9 [15799152.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):1865-74 [10815909.001]
  • [Cites] Eur J Cancer. 1991;27(11):1453-7 [1660295.001]
  • [Cites] J Clin Neurosci. 2008 Jun;15(6):721-2; author reply 722-3 [18406141.001]
  • [Cites] J Neurosurg. 1991 Jun;74(6):861-6 [2033444.001]
  • [Cites] J Neurosurg. 2007 Mar;106(3):455-62 [17367069.001]
  • [Cites] Neurosurgery. 1995 Feb;36(2):365-73; discussion 373-4 [7731518.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E10 [17961034.001]
  • [Cites] J Neurooncol. 1993 Jan;15(1):75-7 [8455065.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):155-66 [15015781.001]
  • [Cites] J Neurooncol. 2002 Jan;56(2):133-42 [11995814.001]
  • [Cites] Gan To Kagaku Ryoho. 2007 Feb;34(2):265-8 [17301541.001]
  • [Cites] Neurochirurgie. 2004 Sep;50(4):461-7 [15547484.001]
  • [Cites] Neurology. 2007 Sep 4;69(10):969-73 [17785665.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1427-30 [15690330.001]
  • [Cites] Neurosurgery. 2006 Nov;59(5):1109-20; discussion 1120-1 [17143245.001]
  • [Cites] Eur J Cancer. 1991;27(4):416-9 [1828169.001]
  • [Cites] Skull Base. 2006 Aug;16(3):157-60 [17268588.001]
  • [Cites] J Neurooncol. 2000 Sep;49(2):165-70 [11206012.001]
  • [Cites] J Neurooncol. 1996 Sep;29(3):269-72 [8858533.001]
  • [Cites] J Neurosurg. 2000 Jul;93(1):132-5 [10883917.001]
  • [Cites] J Neurosurg. 2002 Aug;97(2):341-6 [12186462.001]
  • [Cites] J Neurooncol. 2005 Sep;74(2):157-65 [16193387.001]
  • [Cites] Cancer Invest. 2006 Dec;24(8):727-33 [17162554.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):271-6 [16628476.001]
  • [Cites] Hum Reprod. 1994 Jun;9 Suppl 1:202-7 [7962466.001]
  • [Cites] Clin Neurol Neurosurg. 2008 Jul;110(7):645-8 [18471956.001]
  • [Cites] Acta Neurol Scand. 1987 Jun;75(6):434-6 [2888257.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Jun;15(2):187-92 [17525632.001]
  • [Cites] Lancet. 1995 Feb 4;345(8945):331 [7837901.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2269-76 [11489801.001]
  • [Cites] J Neurooncol. 2004 Mar-Apr;67(1-2):221-6 [15072471.001]
  • [Cites] Neurosurgery. 2000 Mar;46(3):692-702; discussion 702-3 [10719866.001]
  • (PMID = 19023520.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal
  • [Number-of-references] 43
  •  go-up   go-down


10. Haegelen C, Morandi X, Riffaud L, Amlashi SF, Leray E, Brassier G: Results of spinal meningioma surgery in patients with severe preoperative neurological deficits. Eur Spine J; 2005 Jun;14(5):440-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of spinal meningioma surgery in patients with severe preoperative neurological deficits.
  • Spinal meningiomas are usually benign, slow-growing tumours and are commonly associated with good patient outcome following surgery.
  • We retrospectively reviewed data from 33 patients with 35 spinal meningiomas treated in our institution over the past 17 years and exhibiting severe preoperative deficits before surgery.
  • It can be concluded from this study, that, in the vast majority of cases, patients harbouring spinal meningioma with severe preoperative deficits can expect a good outcome.
  • [MeSH-major] Meningeal Neoplasms / complications. Meningeal Neoplasms / surgery. Meningioma / complications. Meningioma / surgery. Nervous System Diseases / etiology. Spinal Cord Neoplasms / complications. Spinal Cord Neoplasms / surgery

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Meningioma, spinal.
  • MedlinePlus Health Information. consumer health - Neurologic Diseases.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Neurol. 1999 Dec;52(6):552-62 [10660020.001]
  • [Cites] J Neurosurg. 1995 Aug;83(2):336-41 [7616281.001]
  • [Cites] Surg Neurol. 1996 Nov;46(5):458-63; discussion 463-4 [8874546.001]
  • [Cites] J Neurosurg. 1997 Feb;86(2):233-40 [9010425.001]
  • [Cites] Br J Neurosurg. 1998 Dec;12(6):521-6 [10070460.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1999 Aug;67(2):185-8 [10406986.001]
  • [Cites] Acta radiol. 1953 Aug-Sep;40(2-3):283-300 [13114030.001]
  • [Cites] AMA Arch Neurol Psychiatry. 1954 May;71(5):588-97 [13157688.001]
  • [Cites] AMA Arch Neurol Psychiatry. 1954 Jul;72(1):43-59 [13170854.001]
  • [Cites] JAMA. 1961 Oct 21;178:261-6 [13887881.001]
  • [Cites] Spine (Phila Pa 1976). 2000 Mar 15;25(6):727-31 [10752106.001]
  • [Cites] J Orthop Res. 2001 Jul;19(4):605-13 [11518269.001]
  • [Cites] Surg Gynecol Obstet. 1970 Jul;131(1):15-21 [5419957.001]
  • [Cites] Int Surg. 1971 Nov;56(5):289-303 [5121132.001]
  • [Cites] Anesthesiology. 1973 Jul;39(1):54-8 [4786951.001]
  • [Cites] J Neurosurg. 1979 Mar;50(3):353-60 [422988.001]
  • [Cites] J Neurosurg. 1982 Dec;57(6):804-12 [7143063.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] J Neurosurg. 1987 Sep;67(3):452-5 [3612278.001]
  • [Cites] Acta Neurol Scand. 1988 Jan;77(1):27-30 [3354308.001]
  • [Cites] Neurosurgery. 1989 Aug;25(2):153-60 [2671779.001]
  • [Cites] J Neurosurg. 1989 Dec;71(6):842-5 [2585075.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1993 Oct;56(10):1046-54 [8410001.001]
  • [Cites] Neurosurg Clin N Am. 1994 Apr;5(2):283-91 [8032227.001]
  • [CommentIn] Eur Spine J. 2006 Jan;15(1):2-7 [16411130.001]
  • (PMID = 15959827.001).
  • [ISSN] 0940-6719
  • [Journal-full-title] European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  • [ISO-abbreviation] Eur Spine J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC3454661
  •  go-up   go-down


11. Shah AB, Muzumdar GA, Chitale AR: Meningiomas: report of a hospital-based registry. Indian J Pathol Microbiol; 2005 Oct;48(4):468-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningiomas: report of a hospital-based registry.
  • This is a hospital-based epidemiologic study of meningiomas.
  • Of 1321 central nervous system tumours, meningiomas constituted 21% of the cases, being the second largest category of a single histologic type after astrocytomas.
  • Of the 267 meningiomas studied, 247 were intra-cranial (92.5%).
  • 261 (98%) meningiomas were histologically benign and 5 were malignant meningiomas (1.9%).
  • Of note was the fact, that out of 261 patients with benign meningiomas, 11 succumbed in the immediate post-operative period and in 8 of these cases, the tumour was located at the base of the skull.
  • [MeSH-major] Meningeal Neoplasms / epidemiology. Meningioma / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16366096.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


12. Bartolomei M, Bodei L, De Cicco C, Grana CM, Cremonesi M, Botteri E, Baio SM, Aricò D, Sansovini M, Paganelli G: Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma. Eur J Nucl Med Mol Imaging; 2009 Sep;36(9):1407-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma.
  • PURPOSE: Meningiomas are generally benign and in most cases surgery is curative.
  • However, for high-grade histotypes or partially resected tumours, recurrence is fairly common.
  • We assessed peptide receptor radionuclide therapy (PRRT) using (90)Y-DOTATOC in a group of patients with meningioma recurring after standard treatments in all of whom somatostatin receptors were strongly expressed on meningioma cell surfaces.
  • METHODS: Twenty-nine patients with scintigraphically proven somatostatin subtype 2 receptor-positive meningiomas were enrolled: 14 had benign (grade I), 9 had atypical (grade II) and 6 had malignant (grade III) disease.
  • Better results were obtained in patients with grade I meningioma than in those with grade II-III, with median time to progression (from beginning PRRT) of 61 months in the low-grade group and 13 months in the high-grade group.
  • CONCLUSION: PRRT with (90)Y-DOTATOC can interfere with the growth of meningiomas.
  • [MeSH-major] Meningeal Neoplasms / radiotherapy. Meningioma / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Octreotide / analogs & derivatives. Radiopharmaceuticals / therapeutic use. Receptors, Somatostatin / metabolism

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Endocrinol Invest. 2005;28(11 Suppl International):132-6 [16625862.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Jul;31(7):1038-46 [15150675.001]
  • [Cites] J Nucl Med. 2006 Oct;47(10):1599-606 [17015894.001]
  • [Cites] Semin Nucl Med. 2002 Apr;32(2):133-40 [11965608.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Mar;74(3):543-7 [1346787.001]
  • [Cites] Digestion. 1993;54 Suppl 1:76-83 [8103015.001]
  • [Cites] J Clin Endocrinol Metab. 1986 Aug;63(2):433-8 [3013920.001]
  • [Cites] Cancer Biother Radiopharm. 2004 Feb;19(1):65-71 [15068613.001]
  • [Cites] Surg Neurol. 1989 Apr;31(4):255-60 [2928917.001]
  • [Cites] Neurosurgery. 2005 Jul;57(1 Suppl):107-13; discussion 107-13 [15987576.001]
  • [Cites] Biopolymers. 2002;66(6):393-8 [12658726.001]
  • [Cites] J Neurosurg. 1991 Jun;74(6):861-6 [2033444.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Hereditas. 1972;71(1):163-8 [4142025.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Feb;30(2):207-16 [12552338.001]
  • [Cites] Neurosurgery. 2005 Sep;57(3):538-50; discussion 538-50 [16145534.001]
  • [Cites] Acta Oncol. 2007;46(6):723-34 [17653893.001]
  • [Cites] J Nucl Med. 2006 Sep;47(9):1467-75 [16954555.001]
  • [Cites] Neurology. 2007 Sep 4;69(10):969-73 [17785665.001]
  • [Cites] J Neurosurg. 2006 Aug;105(2):163-73 [17219818.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1538-47 [11920512.001]
  • [Cites] J Clin Neurosci. 2007 Aug;14(8):747-53 [17499508.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2007 May;34(5):772-86 [17268773.001]
  • [Cites] Expert Rev Neurother. 2006 Oct;6(10):1447-64 [17078786.001]
  • [Cites] J Neurosurg. 1994 Feb;80(2):195-201 [8283256.001]
  • [Cites] Surg Neurol. 1986 Mar;25(3):233-42 [3945904.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Nov;33(11):1346-51 [16847654.001]
  • [Cites] J Neurosurg. 1984 Jan;60(1):52-60 [6689728.001]
  • [Cites] J Neurooncol. 1998 Apr;37(2):177-88 [9524097.001]
  • [Cites] Lancet. 1974 Feb 23;1(7852):277-9 [4130470.001]
  • [Cites] Semin Nucl Med. 2002 Apr;32(2):141-7 [11965609.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):427-36 [9308947.001]
  • [Cites] Pediatr Neurosci. 1988;14(6):319-23 [3270054.001]
  • [Cites] Eur J Nucl Med. 2001 Apr;28(4):426-34 [11357492.001]
  • [Cites] J Nucl Med. 2005 May;46(5):763-9 [15872348.001]
  • [Cites] Am J Clin Oncol. 1986 Aug;9(4):337-40 [3751972.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] Can J Neurol Sci. 1997 Nov;24(4):302-6 [9398976.001]
  • [Cites] Humangenetik. 1972;14(2):167-9 [4112733.001]
  • [Cites] Invest New Drugs. 1992 Nov;10(4):239-53 [1487397.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):299-304 [3403313.001]
  • [Cites] J Nucl Med. 1998 Nov;39(11):1913-7 [9829583.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2754-62 [15837990.001]
  • (PMID = 19319527.001).
  • [ISSN] 1619-7089
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0 / Receptors, Somatostatin; 0 / Yttrium Radioisotopes; 0 / somatostatin receptor 2; RWM8CCW8GP / Octreotide; U194AS08HZ / Edotreotide
  •  go-up   go-down


13. Huang BY, Castillo M: Nonadenomatous tumors of the pituitary and sella turcica. Top Magn Reson Imaging; 2005 Jul;16(4):289-99
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While pituitary adenomas make up over 90% of all sellar masses, there are a number of less known tumors, both malignant and benign, which may arise within the sella turcica.
  • These include relatively common tumors such as meningiomas and craniopharyngiomas, as well as extremely rare tumors such as pituitary astrocytomas and granular cell tumors.
  • [MeSH-major] Craniopharyngioma / diagnosis. Ganglioneuroma / diagnosis. Granular Cell Tumor / diagnosis. Lymphoma / diagnosis. Meningioma / diagnosis. Pituitary Neoplasms / diagnosis. Sella Turcica / pathology

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16785844.001).
  • [ISSN] 0899-3459
  • [Journal-full-title] Topics in magnetic resonance imaging : TMRI
  • [ISO-abbreviation] Top Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 80
  •  go-up   go-down


14. Nakane Y, Natsume A, Wakabayashi T, Oi S, Ito M, Inao S, Saito K, Yoshida J: Malignant transformation-related genes in meningiomas: allelic loss on 1p36 and methylation status of p73 and RASSF1A. J Neurosurg; 2007 Aug;107(2):398-404
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation-related genes in meningiomas: allelic loss on 1p36 and methylation status of p73 and RASSF1A.
  • OBJECT: Analysis of meningiomas supports the suggestion that loss of heterozygosity (LOH) of chromosome arm 1p plays an important role in malignancy.
  • The aim of this study was to identify genes related to meningioma progression from the benign state to the atypical and anaplastic states by examining 1p LOH and the promoter methylation of RASSF1A and p73.
  • METHODS: The authors studied 40 surgical specimens (22 WHO Grade I, 11 Grade II, and seven Grade III) obtained in 37 patients with meningioma.
  • RESULTS: No 1p LOH was detected in the Grade I tumors, whereas it was detected in more than 80% of the Grade II and III tumors.
  • Methylation of the p73 promoter was observed in 81.8 and 71.4% of the Grade II and III tumors, respectively, but it was not observed in any of the Grade I tumors; methylation of the RASSF1A promoter was observed in 18.2, 63.6, and 42.9% of the Grade I, II, and III tumors, respectively.
  • Interestingly, 1p LOH and p73 promoter hypermethylation were detected in the malignantly transformed tumors but not in the lower-grade primary ones.
  • CONCLUSIONS: Based on the hypothesis that meningiomas cumulatively acquire genetic alterations and thus progress from the benign to the atypical and anaplastic states, genetic alterations in the methylation status of p73 or RASSF1A along with 1p LOH may result in the malignant transformation of a meningioma.
  • [MeSH-major] Chromosomes, Human, Pair 1 / genetics. DNA-Binding Proteins / genetics. Loss of Heterozygosity / genetics. Meningeal Neoplasms / genetics. Meningioma / genetics. Nuclear Proteins / genetics. Tumor Suppressor Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17695396.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / RASSF1 protein, human; 0 / Tumor Suppressor Proteins; 0 / tumor suppressor protein p73
  •  go-up   go-down


15. Lee M, Kalani MY, Cheshier S, Gibbs IC, Adler JR, Chang SD: Radiation therapy and CyberKnife radiosurgery in the management of craniopharyngiomas. Neurosurg Focus; 2008;24(5):E4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: Many benign intracranial tumors are amenable to radiotherapy treatment including meningiomas, schwannomas, pituitary tumors, and craniopharyngiomas.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18447743.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 55
  •  go-up   go-down


16. Rogers L, Gilbert M, Vogelbaum MA: Intracranial meningiomas of atypical (WHO grade II) histology. J Neurooncol; 2010 Sep;99(3):393-405
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial meningiomas of atypical (WHO grade II) histology.
  • Atypical (WHO grade II) meningiomas occupy an intermediate risk group between benign (WHO grade I) and anaplastic (WHO grade III) meningiomas.
  • Although grade II meningiomas have traditionally been recognized in only about 5% of cases, after changes in diagnostic criteria with the current 2007 WHO standards, they now comprise approximately 20-35% of all meningiomas.
  • Given the magnitude of this change, much work is now needed to solidify the adoption of these standards, to render inter-observer and inter-institutional comparisons more uniform, and to more carefully define the incidence of grade II histology.
  • We will discuss the definition, diagnosis, and treatment of patients with atypical meningioma; review the current phase II cooperative trials; and draw attention to some questions timely for pre-clinical and clinical research.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Recurrence, Local / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 2009 Jan;64(1):56-60; discussion 60 [19145156.001]
  • [Cites] Radiology. 1987 Aug;164(2):521-6 [3496626.001]
  • [Cites] J Neurooncol. 2000 Jun;48(2):151-60 [11083080.001]
  • [Cites] Clin Nucl Med. 2005 Nov;30(11):717-20 [16237292.001]
  • [Cites] J Neurooncol. 2007 Aug;84(1):41-7 [17361335.001]
  • [Cites] Neurol Res. 1999 Oct;21(7):640-4 [10555183.001]
  • [Cites] Acta Neurochir (Wien). 1995;135(3-4):171-8 [8748810.001]
  • [Cites] J Neurosurg. 2000 May;92(5):766-70 [10794289.001]
  • [Cites] J Neurosurg. 1997 May;86(5):793-800 [9126894.001]
  • [Cites] Brain Pathol. 2003 Jul;13(3):386-408 [12946028.001]
  • [Cites] Int J Cancer. 2003 May 10;104(6):728-34 [12640680.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):801-6 [12788188.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):639-48 [8334619.001]
  • [Cites] Eur J Radiol. 2006 Oct;60(1):48-55 [16844335.001]
  • [Cites] J Neurosurg. 1999 Sep;91(3):384-90 [10470811.001]
  • [Cites] Neurol Res. 2007 Jan;29(1):43-6 [17427274.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Jun;29(6):1147-52 [18356472.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Clin Radiol. 2007 Feb;62(2):109-19 [17207692.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):99-105 [11163502.001]
  • [Cites] Neuroradiology. 1990;32(6):467-73 [2287373.001]
  • [Cites] Neuropathol Appl Neurobiol. 2005 Apr;31(2):141-9 [15771707.001]
  • [Cites] Neurosurgery. 1993 Sep;33(3):394-9; discussion 399 [8413869.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):858-63 [17379447.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Mar 1;34(4):817-22 [8598358.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Feb;17 (2):345-53 [8938309.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(9):921-32 [10526073.001]
  • [Cites] Neurosurgery. 2009 Feb;64(2 Suppl):A7-13 [19165077.001]
  • [Cites] Clin Nucl Med. 2009 Jan;34(1):7-10 [19092373.001]
  • [Cites] J Clin Neurosci. 2003 Sep;10(5):589-93 [12948465.001]
  • [Cites] Neuroradiology. 2006 Aug;48(8):513-20 [16786348.001]
  • [Cites] J Neurosurg. 1999 Dec;91(6):928-34 [10584837.001]
  • [Cites] Neurosurgery. 2005 Dec;57(6):1088-95; discussion 1088-95 [16331155.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1538-47 [11920512.001]
  • [Cites] Osaka City Med J. 1997 Dec;43(2):209-23 [9540343.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Oct;29(9):1630-5 [18583409.001]
  • [Cites] Chin Med J (Engl). 2008 Dec 5;121(23):2415-9 [19102960.001]
  • [Cites] Neurosurgery. 2003 Jul;53(1):62-70; discussion 70-1 [12823874.001]
  • [Cites] J Neurosurg. 2005 Jan;102 Suppl:283-6 [15662826.001]
  • [Cites] Clin Imaging. 2008 Jan-Feb;32(1):22-7 [18164390.001]
  • [Cites] Ann N Y Acad Sci. 1982;381:6-16 [6953802.001]
  • [Cites] Neurosurgery. 1993 Dec;33(6):955-63 [8134008.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2009 Oct;36(10 ):1574-82 [19377904.001]
  • [Cites] Strahlenther Onkol. 1998 Dec;174(12):624-8 [9879349.001]
  • [Cites] Surg Neurol. 2004 Feb;61(2):171-3 [14751635.001]
  • [Cites] Neurosurg Rev. 2006 Oct;29(4):293-6; discussion 296-7 [16953450.001]
  • [Cites] Am J Clin Oncol. 2005 Feb;28(1):70-4 [15685038.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • [Cites] Neurosurgery. 2010 Apr;66(4):661-8; discussion 668-9 [20305491.001]
  • [Cites] Neurosurgery. 2001 Nov;49(5):1029-37; discussion 1037-8 [11846894.001]
  • [Cites] Neurosurgery. 2008 May;62(5 Suppl):A19-27; discussion A27-8 [18580776.001]
  • [Cites] Eur Radiol. 2003 Mar;13(3):582-91 [12594562.001]
  • [Cites] J Neurosurg. 1989 Nov;71(5 Pt 1):665-72 [2809720.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):57-61 [10656373.001]
  • [Cites] J Neurooncol. 1998 Aug;39(1):65-70 [9760071.001]
  • [Cites] Curr Opin Neurol. 2010 Dec;23(6):563-70 [20885321.001]
  • [Cites] Radiologia. 2009 Jul-Aug;51(4):411-9 [19552929.001]
  • [Cites] J Neurosurg. 1996 Jun;84(6):946-50 [8847588.001]
  • [Cites] Acta Neurochir Suppl. 1996;65:108-11 [8738510.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):427-36 [9308947.001]
  • [Cites] J Nucl Med. 1997 Jan;38(1):26-30 [8998144.001]
  • [Cites] Surg Neurol. 2003 Oct;60(4):298-305; discussion 305 [14505844.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Jan;22(1):65-72 [11158890.001]
  • [Cites] Neurosurg Focus. 2008;24(5):E3 [18447742.001]
  • [Cites] Radiology. 2005 Jun;235(3):985-91 [15833979.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E4 [17961041.001]
  • [Cites] J Neuroradiol. 1992;19(1):49-62 [1564530.001]
  • [Cites] Surg Neurol. 1986 Nov;26(5):461-9 [3764651.001]
  • [Cites] Mayo Clin Proc. 1998 Oct;73(10):936-42 [9787740.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):399-406 [19203844.001]
  • (PMID = 20740303.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


17. Vogelbaum MA, Leland Rogers C, Linskey MA, Mehta MP: Opportunities for clinical research in meningioma. J Neurooncol; 2010 Sep;99(3):417-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Opportunities for clinical research in meningioma.
  • Meningiomas, when benign, are commonly treated with surgical resection alone.
  • However, the optimal treatment for patients with subtotally resected or recurrent World Health Organization (WHO) grade I tumors, or WHO grade II and III tumors, regardless of the extent of resection, is not well defined, with both a paucity of high quality published evidence as well as a perceived minimal clinical effect for currently available interventions, specifically in terms of prolonging survival.
  • In consideration of the size of the patient population with incompletely treated or non-benign meningiomas, there are opportunities for conducting high quality, prospective, multicenter clinical trials.
  • [MeSH-major] Biomedical Research. Meningeal Neoplasms / pathology. Meningioma / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 2009 Jan;64(1):56-60; discussion 60 [19145156.001]
  • [Cites] J Neurosurg. 2000 May;92(5):766-70 [10794289.001]
  • [Cites] J Neurooncol. 1992 Jun;13(2):157-64 [1432033.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):801-6 [12788188.001]
  • [Cites] Neuro Oncol. 2009 Dec;11(6):853-60 [19293394.001]
  • [Cites] Br J Neurosurg. 2007 Dec;21(6):588-92 [18071986.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Neuropathol Appl Neurobiol. 2005 Apr;31(2):141-9 [15771707.001]
  • [Cites] Neurosurgery. 1993 Sep;33(3):394-9; discussion 399 [8413869.001]
  • [Cites] J Neurooncol. 1993 Jan;15(1):75-7 [8455065.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(9):921-32 [10526073.001]
  • [Cites] Neurosurgery. 2005 Dec;57(6):1088-95; discussion 1088-95 [16331155.001]
  • [Cites] Neurosurgery. 2000 Mar;46(3):567-74; discussion 574-5 [10719852.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):427-36 [9308947.001]
  • [Cites] J Neurooncol. 2010 Jan;96(2):211-7 [19562255.001]
  • [Cites] Neurosurg Focus. 2008;24(5):E3 [18447742.001]
  • [Cites] Neurosurg Focus. 2003 May 15;14 (5):e4 [15669815.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):299-304 [3403313.001]
  • [Cites] Surg Neurol. 1986 Nov;26(5):461-9 [3764651.001]
  • [Cites] Mayo Clin Proc. 1998 Oct;73(10):936-42 [9787740.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • (PMID = 20835750.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


18. Somerset HL, Kleinschmidt-DeMasters BK, Rubinstein D, Breeze RE: Osteochondroma of the convexity: pathologic-neuroimaging correlates of a lesion that mimics high-grade meningioma. J Neurooncol; 2010 Jul;98(3):421-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteochondroma of the convexity: pathologic-neuroimaging correlates of a lesion that mimics high-grade meningioma.
  • Intracranial chondromas are uncommon benign lesions usually attached to dura and located over the convexity of the skull.
  • Osteochondromas are even rarer and additionally contain a benign bony component.
  • Both lesions are reportedly difficult to distinguish from meningiomas on pre-operative neuroimaging studies, although few detailed pathologic-neuroimaging correlation studies have appeared in the literature, particularly for intracranial osteochondromas.
  • The bright signals were interpreted as showing multifocal hemorrhage and the mass was felt to be a convexity meningioma.
  • Extensive histological sectioning revealed a benign osteochondroma predominantly composed of lobules of hypocellular cartilage.
  • Microdissection of the different components revealed that the multifocal, spicule-like bright foci interpreted as hemorrhage on neuroimaging studies were instead foci of benign bone containing metaplastic bone marrow with trilineage hematopoietic cell populations and adipose tissue.
  • Rare convexity osteochondromas may be mistaken for high-grade meningiomas on neuroimaging studies; their avascular nature, coupled with their complex signal pattern can serve as clues to the correct pre-operative diagnosis.
  • [MeSH-major] Bone Neoplasms / pathology. Dura Mater / pathology. Meningeal Neoplasms / physiopathology. Meningioma / physiopathology. Osteochondroma / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Osteochondroma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Neurosci. 2003 Jan;10(1):106-8 [12464537.001]
  • [Cites] Br J Neurosurg. 1998 Aug;12 (4):380-4 [10070437.001]
  • [Cites] Skull Base Surg. 1997;7(1):49-55 [17171008.001]
  • [Cites] J Neurosurg. 2001 Feb;94(2):331-4 [11213975.001]
  • [Cites] J Neurooncol. 2006 Oct;80(1):21-5 [16937014.001]
  • [Cites] J Clin Neurosci. 2008 Dec;15(12):1406-9 [18842412.001]
  • [Cites] AJNR Am J Neuroradiol. 1989 Sep-Oct;10(5 Suppl):S7-8 [2505578.001]
  • [Cites] J Neurosurg. 1998 Mar;88(3):610 [9488323.001]
  • [Cites] Neurosurgery. 1985 Mar;16(3):412-5 [3982625.001]
  • [Cites] Pediatr Neurosurg. 1991-1992;17(1):53-6 [1811715.001]
  • [Cites] Clin Radiol. 1968 Jul;19(3):327-33 [5302924.001]
  • [Cites] Int J Oral Maxillofac Surg. 2007 Oct;36(10 ):959-62 [17629457.001]
  • [Cites] J Comput Assist Tomogr. 1981 Feb;5(1):109-15 [6972390.001]
  • [Cites] Neurochirurgie. 2007 Dec;53(6):491-4 [18061630.001]
  • [Cites] Neurocirugia (Astur). 2007 Jun;18(3):241-6 [17622464.001]
  • [Cites] Brain Pathol. 2003 Jul;13(3):419-20, 423 [12946032.001]
  • [Cites] Surg Neurol. 1993 Dec;40(6):495-8 [8235973.001]
  • [Cites] Br J Dermatol. 1977 Mar;96(3):317-22 [869989.001]
  • (PMID = 20012156.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. McGovern SL, Aldape KD, Munsell MF, Mahajan A, DeMonte F, Woo SY: A comparison of World Health Organization tumor grades at recurrence in patients with non-skull base and skull base meningiomas. J Neurosurg; 2010 May;112(5):925-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparison of World Health Organization tumor grades at recurrence in patients with non-skull base and skull base meningiomas.
  • OBJECT: Despite a favorable outcome for most patients with WHO Grade I meningiomas, a subset of these patients will have recurrent or progressive disease that advances to a higher grade and requires increasingly aggressive therapy.
  • The goal of this study was to identify clinical characteristics associated with the recurrence of benign meningiomas and their acceleration to atypical and malignant histological types.
  • METHODS: Records of 216 patients with WHO Grade I, II, or III meningioma that were initially treated between 1965 and 2001 were retrospectively reviewed.
  • RESULTS: Patients with non-skull base cranial meningiomas (82 of 105 [78%]) were more likely to have undergone a gross-total resection than patients with skull base meningiomas (32 of 78 [41%]; p < 0.001).
  • Consequently, patients with Grade I non-skull base cranial meningiomas had better 5-year recurrence-free survival (69%) than patients with Grade I skull base meningiomas (56%) or Grade II or III tumors at any site (50%; p = 0.005).
  • Unexpectedly, patients with non-skull base tumors who experienced a recurrence (8 of 22 [36%]) were more likely than patients with skull base tumors (1 of 19 [5%]) to have a higher grade tumor at recurrence (p = 0.024).
  • Furthermore, the median MIB-1 labeling index of Grade I non-skull base cranial meningiomas (2.60%) was significantly higher than that of Grade I skull base tumors (1.35%; p = 0.016).
  • CONCLUSIONS: Cranial meningiomas that occur outside of the skull base are more likely to have a higher MIB-1 labeling index and recur with a higher grade than those within the skull base, suggesting that non-skull base cranial tumors may have a more aggressive biology than skull base tumors.
  • [MeSH-major] Brain Neoplasms / pathology. Meningioma / pathology. Neoplasm Recurrence, Local. Skull Base Neoplasms / pathology. World Health Organization

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19799498.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Wibom C, Mörén L, Aarhus M, Knappskog PM, Lund-Johansen M, Antti H, Bergenheim AT: Proteomic profiles differ between bone invasive and noninvasive benign meningiomas of fibrous and meningothelial subtype. J Neurooncol; 2009 Sep;94(3):321-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic profiles differ between bone invasive and noninvasive benign meningiomas of fibrous and meningothelial subtype.
  • Meningiomas of WHO grade I can usually be cured by surgical resection.
  • However, some tumors may, despite their benign appearance, display invasive growth behavior.
  • By histology alone, bone invasive meningiomas may be indistinguishable from their noninvasive counterparts.
  • In this study we have examined the protein spectra in a series of meningiomas in search of protein expression patterns that may distinguish between bone invasive and noninvasive meningiomas.
  • Tumor tissue from 13 patients with fibrous (6 invasive and 7 noninvasive) and 29 with meningothelial (10 invasive and 19 noninvasive) grade I meningiomas were analyzed by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI).
  • Comparing the protein spectra from invasive and noninvasive fibrous meningioma we found 22 peaks whose intensities were significantly different between the two groups (P < 0.001).
  • In meningothelial meningioma the same comparison yielded six significantly differentially expressed peaks (P < 0.001), which to a large degree separated the invasive from noninvasive tissue (area under ROC curve = 0.873).
  • By analyzing the protein spectra in benign meningiomas we could differentiate between invasive and noninvasive growth behavior in both fibrous and meningothelial meningiomas of grade I.
  • A possibility for early identification of invasive grade I meningiomas may have a strong influence on the follow-up policy and the issue of early or late radiotherapy.
  • [MeSH-major] Bone Neoplasms / metabolism. Bone Neoplasms / secondary. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Invasiveness / pathology. Proteomics

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Proteome Res. 2005 May-Jun;4(3):698-708 [15952716.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):10199-204 [17047085.001]
  • [Cites] Cancer Sci. 2007 Feb;98(2):201-13 [17233837.001]
  • [Cites] Neurosurgery. 2008 Jan;62(1):53-8; discussion 58-60 [18300891.001]
  • [Cites] J Proteome Res. 2007 Jun;6(6):2113-20 [17428078.001]
  • [Cites] Cancer Biol Ther. 2007 Mar;6(3):343-5 [17471020.001]
  • [Cites] Prostate. 2004 Sep 1;60(4):325-31 [15264244.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Apr 5;292(3):587-92 [11922607.001]
  • [Cites] Anticancer Res. 2004 Jul-Aug;24(4):2319-24 [15330178.001]
  • [Cites] J Neurosurg. 2007 Nov;107(5):905-12 [17977259.001]
  • [Cites] Acta Neurol Scand. 1993 Mar;87(3):243-7 [8475698.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:139-46 [16515582.001]
  • [Cites] Prog Neurol Surg. 2007;20:142-9 [17317982.001]
  • [Cites] J Urol. 2005 Jan;173(1):73-8 [15592032.001]
  • [Cites] Anal Chem. 2008 Jan 1;80(1):115-22 [18027910.001]
  • [Cites] Electrophoresis. 2000 Apr;21(6):1164-77 [10786889.001]
  • [Cites] Strahlenther Onkol. 2006 Nov;182(11):635-40 [17072520.001]
  • [Cites] Surg Neurol. 1997 Nov;48(5):501-6 [9352816.001]
  • [Cites] Neurosurgery. 2007 Dec;61(6):1194-8; discussion 1198 [18162898.001]
  • [Cites] J Neurosurg. 2006 Jul;105(1):60-4 [16871881.001]
  • [Cites] Cancer Biol Ther. 2007 Mar;6(3):391-6 [17264672.001]
  • [Cites] Neuropathology. 2007 Oct;27(5):407-12 [18018472.001]
  • [Cites] Br J Cancer. 2006 Jun 19;94(12):1853-63 [16736004.001]
  • [Cites] J Neurosurg. 1983 Sep;59(3):461-6 [6310067.001]
  • [Cites] J Clin Neurosci. 2001 May;8 Suppl 1:44-8 [11386825.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E3 [17961040.001]
  • [Cites] Gynecol Oncol. 2006 Feb;100(2):247-53 [16229881.001]
  • [Cites] Clin Chem. 2006 Nov;52(11):2103-6 [16990423.001]
  • [Cites] Clin Chem. 2005 Jan;51(1):102-12 [15613711.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1002-14 [18281532.001]
  • [Cites] Stereotact Funct Neurosurg. 2005;83(1):45-51 [15860936.001]
  • (PMID = 19350207.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


21. Brunner EC, Romeike BF, Jung M, Comtesse N, Meese E: Altered expression of beta-catenin/E-cadherin in meningiomas. Histopathology; 2006 Aug;49(2):178-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered expression of beta-catenin/E-cadherin in meningiomas.
  • AIMS: Meningiomas are generally slow-growing benign tumours representing approximately 20% of all primary intracranial tumours.
  • The hallmark of tumorigenesis of meningiomas is the loss of chromosome 22, including loss of heterozygosity of the neurofibromatosis type 2 (NF2) gene.
  • The aim of this study was to analyse the expression and the subcellular location of E-cadherin and beta-catenin in human meningiomas, including meningiomas of different histomorphological subtypes and different World Health Organization (WHO) grades.
  • METHODS AND RESULTS: Immunohistochemical analysis revealed lack of E-cadherin expression at the cell membrane in 34% of meningiomas independent of their WHO grade.
  • Loss of membranous beta-catenin occurred in 79% of meningiomas.
  • An intense perinuclear granular immunoreactivity of beta-catenin without nuclear location was detected in the majority of meningiomas.
  • Both immunofluorescence and Western blot analysis of fractionated meningioma cells located beta-catenin mostly on the Golgi apparatus and ER/Golgi intermediate compartment (ERGIC).
  • Cytogenetic analysis of meningiomas showed no correlation between NF2 loss and the loss of the proper location of beta-catenin.
  • CONCLUSIONS: The lack of membranous beta-catenin and/or membranous E-cadherin in meningiomas may indicate an altered interaction between meningioma cells independent of loss of NF2 and independent of the tumour grade.
  • [MeSH-major] Cadherins / biosynthesis. Meningeal Neoplasms / pathology. Meningioma / pathology. beta Catenin / biosynthesis

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16879395.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cadherins; 0 / Neurofibromin 2; 0 / beta Catenin
  •  go-up   go-down


22. De Moura J, Kavalec FL, Doghman M, Rosati R, Custodio G, Lalli E, Cavallari GM, Santa Maria J, Figueiredo BC: Heterozygous TP53stop146/R72P fibroblasts from a Li-Fraumeni syndrome patient with impaired response to DNA damage. Int J Oncol; 2010 Apr;36(4):983-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In order to investigate the disruption of the p53 function in a patient presenting this mutation and the TP53Arg72Pro polymorphism who had so far suffered five malignant tumors and a benign meningioma, we tested her fibroblasts in response to DNA damage by evaluating the proliferation rate, apoptosis, and disruption of the TP53 pathway.
  • The proband's heterozygous fibroblasts were not as efficient as control fibroblasts or those of her mother, who carried only the TP53Arg72Pro polymorphism, in causing cell arrest and cell death after DNA damage, which was correlated with diminished TP21 protein levels.

  • Genetic Alliance. consumer health - Li Fraumeni syndrome.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20198344.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / CDKN1A protein, human; 0 / Codon, Nonsense; 0 / Codon, Terminator; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 6PLQ3CP4P3 / Etoposide
  •  go-up   go-down


23. Al-Khalaf HH, Lach B, Allam A, Hassounah M, Alkhani A, Elkum N, Alrokayan SA, Aboussekhra A: Expression of survivin and p16(INK4a)/Cdk6/pRB proteins and induction of apoptosis in response to radiation and cisplatin in meningioma cells. Brain Res; 2008 Jan 10;1188:25-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of survivin and p16(INK4a)/Cdk6/pRB proteins and induction of apoptosis in response to radiation and cisplatin in meningioma cells.
  • Although meningiomas represent the most common class of tumors of the central nervous system, the molecular events underlying their genesis and development are still not well defined, and therapeutic approaches based on the genetics of these tumors are currently lacking.
  • In the present study we have used the immunoblotting technique to show that the p16(INK4A), Cdk6 and pRB proteins are differentially expressed in primary meningioma cells with 20-, 30- and 36-fold difference between the lowest and the highest levels of each protein, respectively.
  • In addition, we present evidence that the level of the anti-apoptosis survivin protein is high in these benign tumors.
  • Moreover, the annexin V-associated flow cytometry technique was used to show that 60% of meningioma cell cultures underwent apoptosis in response to both gamma-rays and cisplatin, and 50% of these cells exhibited significant sensitivity to hydroxyurea.
  • These data shed more light on the molecular biology of meningioma cells and suggest that survivin and proteins of the RB pathway could play a determinant role in the development and the treatment of meningiomas.
  • [MeSH-major] Apoptosis / physiology. Cyclin-Dependent Kinase 6 / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Microtubule-Associated Proteins / metabolism. Neoplasm Proteins / metabolism. Retinoblastoma Protein / metabolism

  • Genetic Alliance. consumer health - Meningioma.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18048012.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BIRC5 protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Retinoblastoma Protein; 0 / bcl-2-Associated X Protein; EC 2.7.11.22 / CDK6 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 6; Q20Q21Q62J / Cisplatin; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


24. Samadi N, Ahmadi SA: Meningioma: a clinicopathological evaluation. Malays J Med Sci; 2007 Jan;14(1):46-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningioma: a clinicopathological evaluation.
  • As yet no unifying grading system for meningiomas has been adopted.
  • We evaluate epidemiologic factors of meningioma in Iran & degree of agreement between the two commonly used grading systems namely WHO (2000) and Mahmood systems.
  • During a 6-year period 238 meningiomas were selected and reviewed by two independent pathologists using both grading systems.
  • 205(86.1%) cases were benign, 19(8%) atypical and 14(5.9%) malignant.
  • 181(18%) cases were primary and 51(27%) secondary; 35(68%) of the latter benign, 7(14%) atypical and 9(18%) malignant.
  • All intraspinal meningiomas were benign.
  • In benign cranial and spinal types female to male ratios were 1.9: 1 and 1.3: 1 ; while in atypical and malignant types were 1 :1.4 and 1:3.1 respectively.
  • Mean ages were 49.9 for benign.
  • Female preponderance seen in benign nonrecurrent meningioma became increasingly less prominent and even reversed in recurrent, atypical and malignant forms.
  • Benign recurrent tumors were similar to non-recurrent tumors microscopically.
  • Kappa value comparing two grading systems was 0.947, so good agreements were found between Mahmood and WHO grading systems.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Sep 1;89(5):1102-10 [10964341.001]
  • [Cites] Neurol India. 2000 Dec;48(4):338-42 [11146597.001]
  • [Cites] J Pathol. 2001 Jul;194(3):367-72 [11439370.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Oct;60(10):994-1003 [11589430.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1538-47 [11920512.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • [Cites] Neurosurgery. 1993 Dec;33(6):955-63 [8134008.001]
  • [Cites] J Cutan Pathol. 1994 Dec;21(6):549-56 [7699122.001]
  • [Cites] Am J Med Genet. 1994 Oct 1;52(4):450-61 [7747758.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1455-65 [9414189.001]
  • [Cites] J Neurosurg. 1998 Mar;88(3):562-9 [9488313.001]
  • [Cites] J Med Genet. 1992 Dec;29(12):841-6 [1479598.001]
  • (PMID = 22593651.001).
  • [ISSN] 1394-195X
  • [Journal-full-title] The Malaysian journal of medical sciences : MJMS
  • [ISO-abbreviation] Malays J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Malaysia
  • [Other-IDs] NLM/ PMC3351217
  • [Keywords] NOTNLM ; Mahmood grading system / WHO grading system / brain tumor / intracranial / intraspinal / meningioma
  •  go-up   go-down


25. Chung HT, Kim DG, Paek SH, Jung HW: Development of dose-volume relation model for gamma knife surgery of non-skull base intracranial meningiomas. Int J Radiat Oncol Biol Phys; 2009 Jul 15;74(4):1027-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of dose-volume relation model for gamma knife surgery of non-skull base intracranial meningiomas.
  • PURPOSE: To provide a dose-volume relationship for gamma knife surgery (GKS) of non-skull base intracranial meningiomas.
  • METHODS AND MATERIALS: The radiologic outcomes of GKS of 82 imaging-defined benign meningiomas located at non-skull base areas were analyzed.
  • CONCLUSION: This model can be used in GKS to treat small- to medium-size (<9.2 cm(3)) non-skull base meningiomas.
  • [MeSH-major] Brain Neoplasms / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Radiosurgery / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19056186.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


26. Kim YJ, Ketter R, Henn W, Zang KD, Steudel WI, Feiden W: Histopathologic indicators of recurrence in meningiomas: correlation with clinical and genetic parameters. Virchows Arch; 2006 Nov;449(5):529-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathologic indicators of recurrence in meningiomas: correlation with clinical and genetic parameters.
  • Meningiomas in general are circumscribed slow-growing tumors.
  • This study explored the independent prognostic value of potential risk factors among 206 patients who underwent meningioma resection and followed-up until death or a median of 44 months.
  • Among totally resected WHO grade I meningiomas, neither histopathologic nor clinical parameters were predictive, whereas 1p- was the only independent prognostic factor.
  • In particular, biologically aggressive meningiomas of histologically benign or "borderline" phenotype could be therefore identified by ALPL detection followed by 1p in situ hybridization.
  • [MeSH-major] Chromosome Aberrations. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Recurrence, Local / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 1986 Mar;45(2):95-107 [3005518.001]
  • [Cites] Cancer Genet Cytogenet. 1986 Dec;23(4):305-13 [3022913.001]
  • [Cites] Am J Clin Pathol. 2005 Aug;124(2):252-8 [16040297.001]
  • [Cites] Oncogene. 2004 Jan 29;23(4):1014-20 [14749765.001]
  • [Cites] J Neurosurg. 1992 Oct;77(4):616-23 [1527622.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Jun;60(6):628-36 [11398839.001]
  • [Cites] Nature. 1967 Oct 7;216(5110):84-5 [6050684.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Acta Neurochir (Wien). 1995;137(3-4):174-81 [8789658.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1455-65 [9414189.001]
  • [Cites] Cancer Genet Cytogenet. 1982 Jul;6(3):249-74 [6288229.001]
  • [Cites] Clin Neuropathol. 2005 Jul-Aug;24(4):170-4 [16033133.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2262-9 [9610708.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1538-47 [11920512.001]
  • [Cites] J Neurosurg. 2001 Oct;95(4):601-7 [11596954.001]
  • [Cites] J Neurosurg. 1998 May;88(5):831-9 [9576250.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Aug;56(8):879-86 [9258258.001]
  • [Cites] Clin Neuropathol. 2006 Mar-Apr;25(2):67-73 [16550739.001]
  • [Cites] Acta Neurochir (Wien). 2004 Jan;146(1):37-44; discussion 44 [14740263.001]
  • [Cites] Surg Neurol. 1986 Mar;25(3):233-42 [3945904.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Jul 1;120(1):30-6 [10913674.001]
  • [Cites] Cytogenet Cell Genet. 2001;93(3-4):207-20 [11528114.001]
  • [Cites] Am J Surg Pathol. 2001 Apr;25(4):472-8 [11257621.001]
  • [Cites] Arch Pathol Lab Med. 1999 Sep;123(9):793-800 [10458826.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4696-701 [7553651.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jan 15;140(2):99-106 [12645646.001]
  • [Cites] J Neurosurg. 2004 Aug;101(2):210-8 [15309910.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3569-77 [10589773.001]
  • (PMID = 17016718.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


27. Smith JS, Lal A, Harmon-Smith M, Bollen AW, McDermott MW: Association between absence of epidermal growth factor receptor immunoreactivity and poor prognosis in patients with atypical meningioma. J Neurosurg; 2007 Jun;106(6):1034-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between absence of epidermal growth factor receptor immunoreactivity and poor prognosis in patients with atypical meningioma.
  • OBJECT: The clinical behavior of meningiomas is variable.
  • Because multiple growth factor receptors have been identified in these tumors, the authors sought to assess the capacity of the expression patterns of a subset of these receptors to stratify meningioma cases.
  • METHODS: Eighty-four meningiomas were analyzed, including 36 benign, 29 atypical, and 19 malignant lesions.
  • Immunoreactivity for EGFR was observed in 47% of benign, 48% of atypical, and 42% of malignant tumors.
  • Staining for BFGFR was identified in 89% of benign, 97% of atypical, and 95% of malignant lesions.
  • Mean MIB-I indices for benign, atypical, and malignant cases were 3.6 (range 0.5-15.3), 8.2 (range 1.5-23.1) and 18.3 (range 1.0-55.8), respectively.
  • Lack of EGFR immunoreactivity was identified as a strong predictor of shorter overall survival in patients with atypical meningioma (p = 0.003, log-rank test).
  • This association was not evident in cases of benign or malignant meningiomas.
  • CONCLUSIONS: There is a significant association between EGFR immunoreactivity and prolonged survival in patients with atypical meningioma.
  • Given the variable behavior of atypical meningiomas, EGFR assessment could improve existing strategies for patient stratification and treatment.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / pathology. Meningioma / surgery. Receptor, Epidermal Growth Factor / metabolism

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17564176.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-sis; 0 / Receptors, Fibroblast Growth Factor; 103107-01-3 / Fibroblast Growth Factor 2; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


28. Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, Fine HA, Chang SM, Robins HI, Fink K, Deangelis LM, Mehta M, Di Tomaso E, Drappatz J, Kesari S, Ligon KL, Aldape K, Jain RK, Stiles CD, Egorin MJ, Prados MD: Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol; 2009 Dec;11(6):853-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
  • Platelet-derived growth factor (PDGF) and its receptors (PDGFR) are frequently coexpressed in meningiomas, potentially contributing to their pathogenesis.
  • The North American Brain Tumor Consortium conducted a phase II study to evaluate the therapeutic potential of imatinib mesylate (Gleevec), a PDGFR inhibitor, in patients with recurrent meningiomas.
  • Patients were stratified into benign (WHO grade I) meningiomas or atypical (WHO grade II) and malignant (WHO grade III) meningiomas.
  • Twenty-three heavily pretreated patients were enrolled into the study (13 benign, 5 atypical, and 5 malignant meningiomas), of whom 22 were eligible.
  • For benign meningiomas, median PFS was 3 months (range, 1.1-34 months); 6M-PFS was 45%.
  • For atypical and malignant meningiomas, median PFS was 2 months (range, 0.7-3.7 months); 6M-PFS was 0%.
  • Single-agent imatinib was well tolerated but had no significant activity in recurrent meningiomas.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Tumor Pathol. 2001;18(1):1-5 [11517968.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4022-8 [18256322.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] J Neurosurg. 2001 Feb;94(2):293-300 [11213968.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1031-7 [11287972.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1038-42 [11287973.001]
  • [Cites] J Clin Neurosci. 2001 May;8 Suppl 1:49-53 [11386826.001]
  • [Cites] J Neurosurg. 2002 Aug;97(2):341-6 [12186462.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Jul 5;791(1-2):39-44 [12798163.001]
  • [Cites] Neurology. 2004 Apr 13;62(7):1210-2 [15079029.001]
  • [Cites] Acta Neuropathol. 2004 Aug;108(2):135-42 [15148612.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):299-304 [3403313.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Int J Cancer. 1990 Jul 15;46(1):16-21 [2163990.001]
  • [Cites] J Clin Invest. 1990 Jul;86(1):131-40 [2164040.001]
  • [Cites] Int J Cancer. 1990 Nov 15;46(5):772-8 [1699901.001]
  • [Cites] J Biol Chem. 1991 Sep 5;266(25):16755-63 [1653246.001]
  • [Cites] Cancer Res. 1992 Jun 1;52(11):3213-9 [1317261.001]
  • [Cites] J Neurooncol. 1992 Jun;13(2):157-64 [1432033.001]
  • [Cites] J Neurooncol. 1993 Jan;15(1):75-7 [8455065.001]
  • [Cites] J Neurosurg. 1994 Sep;81(3):388-93 [8057146.001]
  • [Cites] Int J Cancer. 1995 Jan 17;60(2):168-73 [7829210.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):100-4 [8548747.001]
  • [Cites] J Neurosurg. 1996 May;84(5):852-8; discussion 858-9 [8622161.001]
  • [Cites] J Neurooncol. 1996 Sep;29(3):197-205 [8858525.001]
  • [Cites] J Neurooncol. 1996 Sep;29(3):261-7 [8858532.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):271-5 [9007858.001]
  • [Cites] J Neurosurg. 1997 May;86(5):840-4 [9126900.001]
  • [Cites] J Neurosurg. 1997 Aug;87(2):315-23 [9254099.001]
  • [Cites] J Neurooncol. 1997 Dec;35(3):289-301 [9440026.001]
  • [Cites] J Neurosurg. 1998 May;88(5):938-9 [9576275.001]
  • [Cites] J Neurosurg. 1999 Jul;91(1):44-50 [10389879.001]
  • [Cites] Science. 2005 Jan 7;307(5706):58-62 [15637262.001]
  • [Cites] Br J Neurosurg. 2004 Oct;18(5):495-9 [15799152.001]
  • [Cites] Clin Pharmacokinet. 2005;44(9):879-94 [16122278.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1702-8 [16033874.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9359-68 [16361636.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):271-6 [16628476.001]
  • [Cites] Br J Clin Pharmacol. 2006 Jul;62(1):97-112 [16842382.001]
  • [Cites] Clin Cancer Res. 2006 Aug 15;12(16):4899-907 [16914578.001]
  • [Cites] Neuro Oncol. 2007 Apr;9(2):145-60 [17293590.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3496-9 [17192396.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E12 [17961036.001]
  • [Cites] PLoS Med. 2008 Jan 29;5(1):e24 [18232729.001]
  • [Cites] Neurosurgery. 2001 Nov;49(5):1029-37; discussion 1037-8 [11846894.001]
  • (PMID = 19293394.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062407; United States / NCRR NIH HHS / RR / M01 RR000079; United States / NCRR NIH HHS / RR / M01 RR003186; United States / NCRR NIH HHS / RR / M01 RR000056; United States / NCRR NIH HHS / RR / M01 RR000865; United States / NCI NIH HHS / CA / U01 CA062399; United States / NCRR NIH HHS / RR / M01 RR000633; United States / NCI NIH HHS / CA / U01 CA062412; United States / NCI NIH HHS / CA / CA 62399; United States / NCI NIH HHS / CA / CA062421-07; United States / NCI NIH HHS / CA / U01 CA062421-07; United States / NCI NIH HHS / CA / U01 CA062421; United States / NCI NIH HHS / CA / U01 CA105663
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta
  • [Other-IDs] NLM/ PMC2802405
  •  go-up   go-down


29. McGuire TP, Palme CE, Perez-Ordonez B, Gilbert RW, Sándor GK: Primary intraosseous meningioma of the calvaria: analysis of the literature and case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Oct;104(4):e34-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary intraosseous meningioma of the calvaria: analysis of the literature and case report.
  • Meningiomas are the most common of the benign intracranial neoplasms.
  • We report the case of a rare primary intraosseous meningioma presenting as a localized, symptom-free supraorbital bony expansion in an 81-year-old female patient and tabulate the previously reported cases of primary intraosseous meningiomas of the craniomaxillofacial region for analysis.
  • [MeSH-major] Frontal Bone / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology. Skull Neoplasms / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17656124.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 81
  •  go-up   go-down


30. Püttmann S, Senner V, Braune S, Hillmann B, Exeler R, Rickert CH, Paulus W: Establishment of a benign meningioma cell line by hTERT-mediated immortalization. Lab Invest; 2005 Sep;85(9):1163-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment of a benign meningioma cell line by hTERT-mediated immortalization.
  • Meningioma represents the most common intracranial tumor, but well-characterized cell lines derived from benign meningiomas are not available.
  • A major reason for the lack of benign tumor cell lines is senescence of nonmalignant cells in vitro, while malignant cells are often immortal.
  • We have developed a meningioma cell line by retrovirally transducing primary cells derived from a human WHO grade I meningothelial meningioma with the human telomerase reverse transcriptase (hTERT) gene, which enables bypassing cellular senescence.
  • One clone, designated Ben-Men-1, was characterized in more detail, and exhibited typical cytological, immunocytochemical, ultrastructural and genetical features of meningioma, including whorl formation, expression of epithelial membrane antigen, desmosomes and interdigitating cell processes, as well as -22q.
  • Following subdural transplantation into nude mice, tumor tissue with typical histological features of meningothelial meningioma was found.
  • We conclude that Ben-Men-1 represents an immortalized yet differentiated cell line useful for biological and therapeutical studies on meningioma.
  • [MeSH-major] Cell Transformation, Neoplastic / genetics. DNA-Binding Proteins / genetics. Meningioma / pathology. Telomerase / genetics

  • Genetic Alliance. consumer health - Meningioma.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15965488.001).
  • [ISSN] 0023-6837
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


31. Hsu CC, Pai CY, Kao HW, Hsueh CJ, Hsu WL, Lo CP: Do aggressive imaging features correlate with advanced histopathological grade in meningiomas? J Clin Neurosci; 2010 May;17(5):584-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do aggressive imaging features correlate with advanced histopathological grade in meningiomas?
  • Atypical and malignant meningiomas are more likely to recur than benign meningiomas.
  • We aimed to distinguish atypical and malignant meningiomas from benign meningiomas based on imaging findings.
  • Between 2004 and 2007, a total of 75 patients with resected intracranial meningiomas were retrospectively reviewed.
  • Histopathological grades were assigned as benign and atypical/malignant meningiomas according to the World Health Organization (WHO) classification.
  • There were 59 benign and 16 atypical/malignant meningiomas.
  • Only intratumoral cystic change and extracranial tumor extension through the skull base foramina were more prevalent in atypical/malignant meningiomas (p=0.001).
  • Hence, these two imaging features might be potential markers of atypical/malignant meningiomas.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningeal Neoplasms / radiography. Meningioma / pathology. Meningioma / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20219376.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


32. Askoxylakis V, Zabel-du Bois A, Schlegel W, Debus J, Huber P, Milker-Zabel S: Patterns of failure after stereotactic radiotherapy of intracranial meningioma. J Neurooncol; 2010 Jul;98(3):367-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of failure after stereotactic radiotherapy of intracranial meningioma.
  • The aim of this work is to evaluate patterns of failure in patients with recurrent meningioma after stereotactic radiotherapy.
  • Of 411 patients with intracranial meningioma treated with radiotherapy at our institution, 22 patients with local tumor progression diagnosed by magnetic resonance imaging (MRI) after radiotherapy (RT) were identified and further investigated.
  • The histologic grade of the meningiomas was World Health Organization (WHO) grade I in 54.5%, WHO grade II in 27.3%, and WHO grade III in 9.1% of cases.
  • Median recurrence-free survival was 46 months for patients with benign meningioma (WHO grade I) and 31.5 months for patients with higher-grade meningioma (WHO grade II/III).
  • In the WHO grade I group, three recurrences were central and nine were marginal, whereas in the WHO grade II/III group seven recurrences were central and one was marginal.
  • Median time to local tumor progression and site of local recurrence significantly depended on histological grade of meningioma.
  • Regarding site of failure, improvement of dose coverage for benign meningiomas and dose escalation for high-grade tumors might further improve therapy outcome.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Radiosurgery / methods

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Feb 1;55(2):362-72 [12527049.001]
  • [Cites] Neurosurg Rev. 2008 Oct;31(4):421-30; discussion 430 [18521636.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):639-48 [8334619.001]
  • [Cites] J Neurosurg. 1999 May;90(5):823-7 [10223446.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):858-63 [17379447.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 Aug;67(2):153-71 [18342535.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3547-53 [11481362.001]
  • [Cites] Cancer Radiother. 1999 Jul-Aug;3(4):311-7 [10486542.001]
  • [Cites] Strahlenther Onkol. 2006 Nov;182(11):635-40 [17072520.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):238-44; discussion 245-7 [9007855.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 30;29(5):1147-55 [8083085.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2009 Sep;36(9):1407-16 [19319527.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1315-24 [10613328.001]
  • [Cites] Methods Enzymol. 2007;435:297-321 [17998060.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):809-16 [15708260.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] Zentralbl Neurochir. 2008 Feb;69(1):14-21 [18393160.001]
  • [Cites] Radiologe. 1998 Mar;38(3):228-34 [9577869.001]
  • (PMID = 20012910.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. El Husseini M, Ianovici N, Dumitrescu GF, Mihăilă D, Plămădeală P, Haba D, Indrei A: [Posterior fossa meningiomas--topographic and anatomopathologic aspects]. Rev Med Chir Soc Med Nat Iasi; 2010 Jul-Sep;114(3):777-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Posterior fossa meningiomas--topographic and anatomopathologic aspects].
  • Meningiomas are the most frequent met intracranial tumors.
  • MATERIAL AND METHOD: Our study is focused on posterior fosa meningiomas, initially classified according to their origin based on IRM and surgical findings in order to identify correlations between demographic data, topographic tumor origin and anatomopathologic characteristics for each subgroup.
  • 35 posterior fosa meningioma patients that have been subject to neurosurgery in Iaşi "Prof.Dr. N.
  • Benign meningiomas (1st degree) represented the unique subtype in tumors located in cerebellum convexity and foramen magnum.
  • Other locations have different characteristic subtypes (fibrous vs. angiomatous meningioma).
  • [MeSH-major] Cranial Fossa, Posterior / pathology. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21243804.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


34. Davidson L, Fishback D, Russin JJ, Weiss MH, Yu C, Pagnini PG, Zelman V, Apuzzo ML, Giannotta SL: Postoperative Gamma Knife surgery for benign meningiomas of the cranial base. Neurosurg Focus; 2007;23(4):E6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative Gamma Knife surgery for benign meningiomas of the cranial base.
  • OBJECT: The standard treatment for meningiomas is complete resection, but the proximity of skull base meningiomas to important neurovascular structures makes complete excision of the lesion difficult or impossible.
  • The authors analyzed the mid- and long-term results obtained in patients treated with postresection Gamma Knife surgery (GKS) for residual or recurrent benign meningiomas of the cranial base.
  • METHODS: Thirty-six patients with residual or recurrent benign meningiomas of the skull base following one or more surgical procedures underwent GKS.
  • It should be initially considered along with surgery for the treatment of complex skull base meningiomas.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Radiosurgery. Skull Base Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961043.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Steiger HJ: Preventive neurosurgery: population-wide check-up examinations and correction of asymptomatic pathologies of the nervous system. Acta Neurochir (Wien); 2006 Oct;148(10):1075-83; discussion 1083
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RATIONALE FOR CHECK-UP IMAGING AND PREVENTIVE TREATMENT: The average prevalence of asymptomatic intracranial benign tumours, aneurysms and carotid stenoses must be estimated as approximately 1% each.
  • Meningiomas, aneurysms and carotid stenosis become more frequent with increasing age.
  • Treatment of the benign tumours, hydrocephalus and arachnoid cysts in the asymptomatic stage does not appear to provide any benefit.


36. Fulkerson DH, Horner TG, Hattab EM: Histologically benign intraventricular meningioma with concurrent pulmonary metastasis: case report and review of the literature. Clin Neurol Neurosurg; 2008 Apr;110(4):416-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologically benign intraventricular meningioma with concurrent pulmonary metastasis: case report and review of the literature.
  • Only 1-2% of all meningiomas are intraventricular in location.
  • Metastasis from a histologically "benign" meningioma is a rare, but well-documented event.
  • However, there are only four reported cases in the literature of metastatic spread from a purely intraventricular meningioma.
  • In this report, the authors present a rare case of the concurrent presentation of a histologically benign intraventricular meningioma and a solitary lung lesion which proved to be metastatic meningioma.
  • [MeSH-major] Cerebral Ventricle Neoplasms / pathology. Lung Neoplasms / secondary. Magnetic Resonance Imaging. Meningeal Neoplasms / pathology. Meningioma / secondary. Tomography, X-Ray Computed


37. Pfisterer WK, Hendricks WP, Scheck AC, Nieman RA, Birkner TH, Krampla WW, Preul MC: Fluorescent in situ hybridization and ex vivo 1H magnetic resonance spectroscopic examinations of meningioma tumor tissue: is it possible to identify a clinically-aggressive subset of benign meningiomas? Neurosurgery; 2007 Nov;61(5):1048-59; discussion 1060-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescent in situ hybridization and ex vivo 1H magnetic resonance spectroscopic examinations of meningioma tumor tissue: is it possible to identify a clinically-aggressive subset of benign meningiomas?
  • OBJECTIVE: Although histologically benign, Grade I meningiomas can sometimes behave aggressively.
  • The clinically-aggressive subset of Grade I meningiomas is typically indistinguishable from clinically-benign Grade I meningiomas in vivo.
  • We compared molecular genetic and biochemical findings to clinical, pathological, and immunohistochemical information in a series of clinically-aggressive Grade I meningiomas with a series of clinically-benign meningiomas to identify characteristics that may be used to distinguish between these two groups.
  • METHODS: Tumor tissue samples from 30 patients with Grade I meningiomas were harvested.
  • RESULTS: Molecular genetic and biochemical findings correlated with clinical behavior of the two Grade I meningioma groups.
  • The presence of aberrations also influenced meningioma regrowth after subtotal resection.
  • Alanine was decreased in meningiomas with chromosomal aberrations in tumors that recurred.
  • CONCLUSION: Distinct molecular genetic and biochemical alterations differentiated clinically-aggressive Grade I meningiomas from clinically-benign Grade I meningiomas.
  • [MeSH-major] Biomarkers, Tumor / analysis. In Situ Hybridization, Fluorescence / methods. Magnetic Resonance Spectroscopy / methods. Meningioma / diagnosis. Meningioma / physiopathology. Neoplasm Proteins / analysis

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18091281.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Protons
  •  go-up   go-down


38. Shimizu J, Matsumoto M, Yamazaki E, Yasue M: Spontaneous regression of an asymptomatic meningioma associated with discontinuation of progesterone agonist administration. Neurol Med Chir (Tokyo); 2008 May;48(5):227-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous regression of an asymptomatic meningioma associated with discontinuation of progesterone agonist administration.
  • The patient had a history of taking chlormadinone acetate (a progesterone agonist) prescribed several years previously as treatment for benign prostatic hypertrophy.
  • The tentative diagnosis was left frontal meningioma attached to the sphenoid ridge or sphenoid plane.
  • The medication for benign prostatic hypertrophy was changed from chlormadinone acetate to naftopidil (an alpha-2-blocker) about 9 months after his first presentation.
  • Thus, we wish to emphasize that treatment of meningiomas, especially those diagnosed incidentally, must be based on a thorough consideration of any history of hormonal therapy with prostate disease.
  • [MeSH-major] Androgen Antagonists / administration & dosage. Chlormadinone Acetate / administration & dosage. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Regression, Spontaneous

  • Genetic Alliance. consumer health - Meningioma.
  • Hazardous Substances Data Bank. CHLORMADINONE ACETATE .
  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18497498.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0SY050L61N / Chlormadinone Acetate; 4G7DS2Q64Y / Progesterone
  •  go-up   go-down


39. Lee JH, Sade B, Choi E, Golubic M, Prayson R: Meningothelioma as the predominant histological subtype of midline skull base and spinal meningioma. J Neurosurg; 2006 Jul;105(1):60-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningothelioma as the predominant histological subtype of midline skull base and spinal meningioma.
  • OBJECT: This study was undertaken to test a hypothesis that meningiomas of the midline skull base and spine are predominantly of the meningothelial histological subtype.
  • METHODS: The cases of 794 consecutive patients who underwent resection for meningioma at the Cleveland Clinic between January 1991 and March 2004 were reviewed retrospectively.
  • The authors analyzed the relationship between the tumors' histological subtypes and sites of origin in the 731 patients from this group who harbored tumors that were determined to be benign histologically (World Health Organization Grade I).
  • Meningothelial meningiomas (MMs) accounted for 63.5% (464/731) of the Grade I tumors.
  • CONCLUSIONS: Meningiomas of the midline neuraxis are predominantly meningotheliomas.
  • Analysis of the increasingly available data on genetic and topographic characteristics of MMs suggests that they may represent a unique entity, contrary to the prevailing belief that all benign meningiomas are identical tumors.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology. Skull Base Neoplasms / pathology. Spinal Cord Neoplasms / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Meningioma, spinal.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16871881.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Zhang H, Rödiger LA, Shen T, Miao J, Oudkerk M: Preoperative subtyping of meningiomas by perfusion MR imaging. Neuroradiology; 2008 Oct;50(10):835-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative subtyping of meningiomas by perfusion MR imaging.
  • INTRODUCTION: This paper aims to evaluate the value of perfusion magnetic resonance (MR) imaging in the preoperative subtyping of meningiomas by analyzing the relative cerebral blood volume (rCBV) of three benign subtypes and anaplastic meningiomas separately.
  • MATERIALS AND METHODS: Thirty-seven meningiomas with peritumoral edema (15 meningothelial, ten fibrous, four angiomatous, and eight anaplastic) underwent perfusion MR imaging by using a gradient echo echo-planar sequence.
  • RESULTS: The mean rCBV of meningothelial, fibrous, angiomatous, and anaplastic meningiomas in tumoral parenchyma were 6.93 +/- 3.75, 5.61 +/- 4.03, 11.86 +/- 1.93, and 5.89 +/- 3.85, respectively, and in the peritumoral edema 0.87 +/- 0.62, 1.38 +/- 1.44, 0.87 +/- 0.30, and 3.28 +/- 1.39, respectively.
  • The mean rCBV in tumoral parenchyma of angiomatous meningiomas and in the peritumoral edema of anaplastic meningiomas were statistically different (p < 0.05) from the other types of meningiomas.
  • CONCLUSION: Perfusion MR imaging can provide useful functional information on meningiomas and help in the preoperative diagnosis of some subtypes of meningiomas.
  • [MeSH-major] Magnetic Resonance Angiography / methods. Meningeal Neoplasms / pathology. Meningioma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2006 Oct 15;66(20):10199-204 [17047085.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Jan;27(1):85-93 [16418363.001]
  • [Cites] J Neurooncol. 2003 Nov;65(2):119-23 [14686730.001]
  • [Cites] Br J Neurosurg. 1998 Oct;12(5):414-8 [10070443.001]
  • [Cites] Acta Neurochir (Wien). 1994;129(1-2):31-8 [7998493.001]
  • [Cites] J Magn Reson Imaging. 2006 Oct;24(4):817-24 [16958061.001]
  • [Cites] Radiology. 2002 Apr;223(1):11-29 [11930044.001]
  • [Cites] Brain Tumor Pathol. 2004;21(3):127-33 [15696974.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Aug;22(7):1306-15 [11498419.001]
  • [Cites] J Neurosurg. 1999 Sep;91(3):384-90 [10470811.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Jun-Jul;26(6):1446-54 [15956514.001]
  • [Cites] J Neuroradiol. 2002 Jun;29(2):105-13 [12297732.001]
  • [Cites] Magn Reson Med. 1990 May;14(2):249-65 [2345506.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Sep;24(8):1554-9 [13679270.001]
  • [Cites] Neuroradiology. 1993;35(7):532-6 [8232883.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Magn Reson Imaging Clin N Am. 2003 Aug;11(3):403-13 [14768726.001]
  • [Cites] Neurosurgery. 1992 Dec;31(6):1015-21; discussion 1021-2 [1281915.001]
  • [Cites] Magn Reson Med. 1988 Feb;6(2):164-74 [3367774.001]
  • [Cites] Eur Radiol. 2002 Aug;12(8):2062-76 [12136325.001]
  • [Cites] Radiology. 1994 Apr;191(1):41-51 [8134596.001]
  • [Cites] Eur Radiol. 2003 Apr;13(4):758-62 [12664114.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Mar;27(3):475-87 [16551981.001]
  • [Cites] Cancer. 1999 Feb 15;85(4):936-44 [10091773.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • [Cites] Radiology. 1999 Jun;211(3):791-8 [10352608.001]
  • (PMID = 18542938.001).
  • [ISSN] 0028-3940
  • [Journal-full-title] Neuroradiology
  • [ISO-abbreviation] Neuroradiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


41. Kalamarides M, Stemmer-Rachamimov AO, Takahashi M, Han ZY, Chareyre F, Niwa-Kawakita M, Black PM, Carroll RS, Giovannini M: Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations. Brain Pathol; 2008 Jan;18(1):62-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.
  • Meningiomas account for approximately 30% of all primary central nervous system tumors and are found in half of neurofibromatosis type 2 patients often causing significant morbidity.
  • Although most meningiomas are benign, 10% are classified as atypical or anaplastic, displaying aggressive clinical behavior.
  • Biallelic inactivation of the neurofibromatosis 2 (NF2) tumor suppressor is associated with meningioma formation in all NF2 patients and 60% of sporadic meningiomas.
  • Deletion of the p16(INK4a)/p14(ARF) locus is found in both benign and malignant meningiomas, while mutation of the p53 tumor suppressor gene is uncommon.
  • Previously, we inactivated Nf2 in homozygous conditional knockout mice by adenoviral Cre delivery and showed that Nf2 loss in arachnoid cells is rate-limiting for meningioma formation.
  • Here, we report that additional nullizygosity for p16(Ink4a) increases the frequency of meningioma and meningothelial proliferation in these mice without modifying the tumor grade.
  • In addition, by using magnetic resonance imaging (MRI) to screen a large cohort of mutant mice, we were able to detect meningothelial proliferation and meningioma development opening the way to future studies in which therapeutic interventions can be tested as preclinical assessment of their potential clinical application.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p16 / genetics. Meningeal Neoplasms / genetics. Meningeal Neoplasms / pathology. Meningioma / genetics. Meningioma / pathology. Neurofibromin 2 / genetics


42. Petrovic NS, Grujicic D, Artiko VM, Sobic-Saranovic DP, Gajic MM, Jaksic E, Grajic MM, Antonovic OJ, Petrovic MN, Obradovic VB: Investigation of blood perfusion and metabolic activity of brain tumours in adults by using 99mTc-methoxyisobutylisonitrile. Nucl Med Commun; 2010 Nov;31(11):962-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Mean P of various brain tumours (low-grade gliomas 0.98, anaplastic gliomas 1.14, glioblastoma multiforme 1.20, metastases 1.09, lymphomas 1.08) differ little from each other and do not exceed maximal physiologic regional variations of cerebral perfusion (1.33), with the exception of meningioma (1.87, F=2.83, P=0.015).
  • The receiver operating characteristics curve analysis of P showed that for the cut-off value of 1.45 the sensitivity for distinguishing meningioma from other tumours is 75%, specificity 87%, positive predictive value 33% and negative predictive value 97%.
  • Mean E of malignant brain tumours (8.3, n=31, 23 primary, eight secondary), except anaplastic gliomas (3.5, n=5), differed significantly (P=0.02) from those of benign gliomas (3, n=9) but not from that of meningioma (11.9, n=4).
  • The cut-off value for distinguishing malignant from benign lesions on the basis of E set at 4.8 resulted in sensitivity 67%, specificity 75%, accuracy 70%, positive predictive value 80% and negative predictive value 60%.
  • D and R showed tendency of wash-out of MIBI from meningiomas, but otherwise did not improve the results substantially.
  • If the perfusion index is less than 1.45, then meningioma can be ruled out.
  • Early SPET is recommendable for distinguishing glioblastoma from low-grade gliomas, as a complement to standard magnetic resonance imaging and/or computed tomography.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20802363.001).
  • [ISSN] 1473-5628
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


43. Ozen O, Demirhan B, Altinörs N: Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas. Clin Neuropathol; 2005 Sep-Oct;24(5):219-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas.
  • OBJECTIVE: Meningiomas for the most part are slow-growing benign tumors, but complete removal can be difficult and recurrence is an issue.
  • The aim of this study was to re-evaluate tumors diagnosed as meningioma previously in our hospital, according to the latest World Health Organization classification.
  • We also examined the relationships among parameters such as brain invasion, histological grade and Ki-67 and p53 expression in these tumors.
  • MATERIALS AND METHODS: Meningioma biopsy specimens numbering 60 (48 grade I, 11 grade II, and 1 grade III tumors) were examined immunohistochemically using monoclonal antibodies for Ki-67 (MIB-1) and p53 protein.
  • RESULTS: Of the 60 meningiomas, 7 (11.7%) exhibited brain invasion.
  • The mean MIB-1 LI values for the grade I and grade II tumors were 1.1% and 2.3%, respectively.
  • The MIB-1 LI and the level of p53 expression in the one grade III meningioma were 6.7% and 10 - 70%, respectively.
  • Histological grade was significantly correlated with MIB-1 LI and with p53 expression (p < 0.01 for both).
  • Brain invasion was not correlated with histological grade, MIB-1 LI, or p53 expression.
  • CONCLUSION: The results indicate that MIB-1 LI and p53 protein expression are good indicators of histological grade in meningioma and may be particularly valuable for distinguishing borderline atypical meningiomas.
  • The number of cases was limited, but the findings also suggest that brain invasion is a prognostic parameter independent of grade, MIB-1 LI and p53 expression.
  • [MeSH-major] Biomarkers, Tumor / analysis. Ki-67 Antigen / biosynthesis. Meningeal Neoplasms / pathology. Meningioma / pathology. Tumor Suppressor Protein p53 / biosynthesis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16167545.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


44. Laurendeau I, Ferrer M, Garrido D, D'Haene N, Ciavarelli P, Basso A, Vidaud M, Bieche I, Salmon I, Szijan I: Gene expression profiling of ErbB receptors and ligands in human meningiomas. Cancer Invest; 2009 Jul;27(6):691-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling of ErbB receptors and ligands in human meningiomas.
  • ErbB family receptors mediate major cellular functions implied in tumorigenesis, though their role in meningiomas was not thoroughly studied.
  • Meningiomas represent 30% of primary cranial tumors, are mostly benign, and prevail in the second half of life.
  • Tumor therapy requires information about molecular alterations, thus we studied expression of ErbB receptor and ligand genes by real-time RT-PCR in different meningioma grades.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Genes, erbB. Intercellular Signaling Peptides and Proteins / genetics. Meningeal Neoplasms / genetics. Meningioma / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19440932.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AREG protein, human; 0 / Amphiregulin; 0 / BTC protein, human; 0 / Betacellulin; 0 / EGF Family of Proteins; 0 / EPGN protein, human; 0 / Epigen; 0 / Glycoproteins; 0 / HBEGF protein, human; 0 / Heparin-binding EGF-like Growth Factor; 0 / Intercellular Signaling Peptides and Proteins; 0 / Ligands; 0 / Neuregulins; 0 / RNA, Messenger; 0 / Transforming Growth Factor alpha; 62229-50-9 / Epidermal Growth Factor; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / ERBB4 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.10.1 / Receptor, ErbB-4
  •  go-up   go-down


45. Raizer J: Meningiomas. Curr Treat Options Neurol; 2010 Jul;12(4):360-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningiomas.
  • OPINION STATEMENT: Meningiomas are extra-axial dural-based tumors.
  • Meningiomas are usually benign, but atypical and malignant forms exist.
  • For higher grade meningiomas, radiation is used after surgery.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2006 Oct;105(4):538-43 [17044555.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):271-5 [9007858.001]
  • [Cites] Brain Pathol. 2003 Jul;13(3):386-408 [12946028.001]
  • [Cites] J Neurooncol. 1990 Feb;8(1):61-5 [2319292.001]
  • [Cites] Br J Neurosurg. 2004 Oct;18(5):495-9 [15799152.001]
  • [Cites] Neuro Oncol. 2009 Dec;11(6):853-60 [19293394.001]
  • [Cites] J Neurosurg. 1991 Jun;74(6):861-6 [2033444.001]
  • [Cites] Neurology. 2004 Sep 28;63(6):1133-4 [15452322.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E12 [17961036.001]
  • [Cites] J Neurooncol. 1993 Jan;15(1):75-7 [8455065.001]
  • [Cites] Neurology. 2007 Sep 4;69(10):969-73 [17785665.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1515-9 [15590183.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Jun;59(6):504-12 [10850863.001]
  • [Cites] J Neurosurg. 1994 Feb;80(2):195-201 [8283256.001]
  • [Cites] J Neurooncol. 1996 Sep;29(3):269-72 [8858533.001]
  • [Cites] Neurology. 2004 Apr 13;62(7):1210-2 [15079029.001]
  • [Cites] J Neurosurg. 1996 May;84(5):733-6 [8622144.001]
  • [Cites] J Neurosurg. 2002 Aug;97(2):341-6 [12186462.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):271-6 [16628476.001]
  • [Cites] J Neurooncol. 2010 Jan;96(2):211-7 [19562255.001]
  • [Cites] Cancer. 2008 Oct 15;113(8):2146-51 [18756531.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):809-16 [15708260.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E4 [17961041.001]
  • [Cites] Surg Neurol. 1986 Nov;26(5):461-9 [3764651.001]
  • (PMID = 20842594.001).
  • [ISSN] 1534-3138
  • [Journal-full-title] Current treatment options in neurology
  • [ISO-abbreviation] Curr Treat Options Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Beall DP, Googe DJ, Emery RL, Thompson DB, Campbell SE, Ly JQ, DeLone D, Smirniotopoulos J, Lisanti C, Currie TJ: Extramedullary intradural spinal tumors: a pictorial review. Curr Probl Diagn Radiol; 2007 Sep-Oct;36(5):185-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The category of extramedullary intradural masses includes a variety of lesions from meningiomas and nerve sheath tumors (neurofibromas, schwannomas) to less common tumors (hemangiopericytoma), metastases, benign tumors (lipoma, dermoid, epidermoid), inflammatory disorders (arachnoid adhesions, sarcoidosis), vascular lesions (spinal-dural arteriovenous fistula), and cystic lesions (perineural or Tarlov cysts).
  • [MeSH-minor] Contrast Media. Diagnosis, Differential. Humans. Meningioma / diagnosis. Nerve Sheath Neoplasms / diagnosis. Prognosis

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17765798.001).
  • [ISSN] 0363-0188
  • [Journal-full-title] Current problems in diagnostic radiology
  • [ISO-abbreviation] Curr Probl Diagn Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 24
  •  go-up   go-down


47. Jolapara M, Kesavadas C, Radhakrishnan VV, Thomas B, Gupta AK, Bodhey N, Patro S, Saini J, George U, Sarma PS: Role of diffusion tensor imaging in differentiating subtypes of meningiomas. J Neuroradiol; 2010 Dec;37(5):277-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of diffusion tensor imaging in differentiating subtypes of meningiomas.
  • PURPOSE: Meningiomas are the most common extraaxial intracranial type of tumor, and their management and prognosis depend on their grade and histology.
  • The aim of the present study was to assess the role of diffusion and diffusion tensor metrics in the identification and classification of meningioma grades and subtypes.
  • METHODS AND MATERIALS: A total of 21 consecutive patients with meningioma were included in this retrospective study, of whom 16 had benign meningiomas (three fibroblastic, 11 transitional/mixed, two meningothelial) and five had atypical meningiomas.
  • Tumor mean diffusivity (Dav), fractional anisotropy (FA), linear anisotropy (CL), planar anisotropy (CP), spherical anisotropy (CS) and eigenvalues (e1, e2, e3) were measured in all cases, and differences in diffusion tensor metrics between atypical, fibroblastic and other benign (transitional, meningothelial) meningiomas were statistically analyzed using the Mann-Whitney test.
  • RESULTS: No statistically significant differences were found among the mean Dav values for atypical, fibroblastic and other benign meningiomas.
  • Both atypical and fibroblastic meningiomas showed significantly higher mean FA values and lower mean CS values compared with other meningiomas (P<0.01), but no statistically significant difference in these values between each other.
  • Atypical meningiomas showed higher CL values compared with fibroblastic and other benign meningiomas but, again, the difference was not statistically significant.
  • Both atypical and fibroblastic meningiomas showed statistically significantly higher CP values and lower e3 values compared with transitional meningiomas (P<0.01).
  • CONCLUSION: These results suggest that diffusion tensor metrics may be helpful in the differentiation of atypical, fibroblastic and other benign meningiomas.
  • [MeSH-major] Diffusion Tensor Imaging. Meningeal Neoplasms / pathology. Meningioma / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20381865.001).
  • [ISSN] 0150-9861
  • [Journal-full-title] Journal of neuroradiology. Journal de neuroradiologie
  • [ISO-abbreviation] J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


48. Zhou YA, Huang JH, Wan CY, Zuo ZB: [Surgical treatment and effect observation of cervical intraspinal benign neoplasms]. Zhongguo Gu Shang; 2009 Nov;22(11):856-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment and effect observation of cervical intraspinal benign neoplasms].
  • OBJECTIVE: To investigate the diagnosis, surgical procedure and clinical outcome of cervical intraspinal benign neoplasm.
  • All underwent X-ray, CT and MRI, 11 cases were diagnosed as neurilemomas, 4 neurofibromas, 3 spinal meningiomas, 2 intraspinal cysts and 2 lipomas.
  • CONCLUSION: The surgical exairesis for cervical intraspinal benign neoplasm has low post-operative recurrence.

  • MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20084949.001).
  • [ISSN] 1003-0034
  • [Journal-full-title] Zhongguo gu shang = China journal of orthopaedics and traumatology
  • [ISO-abbreviation] Zhongguo Gu Shang
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


49. Nakaya K, Niranjan A, Kondziolka D, Kano H, Khan AA, Nettel B, Koebbe C, Pirris S, Flickinger JC, Lunsford LD: Gamma knife radiosurgery for benign tumors with symptoms from brainstem compression. Int J Radiat Oncol Biol Phys; 2010 Jul 15;77(4):988-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma knife radiosurgery for benign tumors with symptoms from brainstem compression.
  • PURPOSE: This study evaluated the role of radiosurgery in the management of symptomatic patients with brainstem compression from benign basal tumors.
  • METHODS AND MATERIALS: Over a 17-year, period 246 patients (202 vestibular schwannomas and 44 meningiomas) with brainstem compression from benign skull-base tumors were managed with Gamma Knife radiosurgery.
  • Median tumor volumes were 3.9 cm(3) (range, 0.8-39.0 mL) and 6.6 mL (range, 1.6-25.1 mL) for vestibular schwannomas and meningiomas, respectively.
  • Median follow-up of patients was 65 months for vestibular schwannomas and 60 months for meningiomas.
  • RESULTS: Preservation of function was stratified according to grade of brainstem compression.
  • The tumor control rate was 100 % for meningioma and 97% for vestibular schwannomas (although 5% required an additional procedure such as a ventriculoperitoneal shunt).
  • Balance improved in 31.9%, remained unchanged in 56.5%, and deteriorated in 11.6% of patients who had imbalance at presentation.
  • Balance improved significantly in patients who had less tumor compression (p = 0.0357) after radiosurgery.
  • Symptoms improved in 43.2% of patients with meningioma.
  • CONCLUSION: Radiosurgery is a minimally invasive option for patients with benign basal tumors that indent or distort the brainstem.
  • [MeSH-major] Brain Stem. Meningeal Neoplasms / surgery. Meningioma / surgery. Neuroma, Acoustic / surgery. Radiosurgery / methods. Skull Base Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20381265.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Bledsoe JM, Link MJ, Stafford SL, Park PJ, Pollock BE: Radiosurgery for large-volume (&gt; 10 cm3) benign meningiomas. J Neurosurg; 2010 May;112(5):951-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiosurgery for large-volume (> 10 cm3) benign meningiomas.
  • OBJECT: Stereotactic radiosurgery (SRS) has proven to be a safe and effective treatment for many patients with intracranial meningiomas.
  • Nevertheless, the morbidity associated with radiosurgery of larger meningiomas is poorly understood.
  • METHODS: The authors performed a retrospective review of 116 patients who underwent SRS for meningiomas (WHO Grade I) > 10 cm3 between 1990 and 2007, with a minimum follow-up of 12 months.
  • Patients with atypical or malignant meningiomas and those who received prior radiotherapy were excluded.
  • CONCLUSIONS: The morbidity associated with SRS for patients with benign meningiomas > 10 cm(3) is greater for supratentorial tumors compared with skull base tumors.
  • Whereas radiosurgery is relatively safe for patients with large-volume skull base meningiomas, resection should remain the primary disease management for the majority of patients with large-volume supratentorial meningiomas.
  • [MeSH-major] Meningioma / pathology. Meningioma / surgery. Radiosurgery / instrumentation. Skull Base Neoplasms / pathology. Skull Base Neoplasms / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg. 2010 Dec;113(6):1335-6; author reply 1336-7 [20887089.001]
  • (PMID = 19764829.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Laurendeau I, Ferrer M, Garrido D, D'Haene N, Ciavarelli P, Basso A, Vidaud M, Bieche I, Salmon I, Szijan I: Gene expression profiling of the hedgehog signaling pathway in human meningiomas. Mol Med; 2010 Jul-Aug;16(7-8):262-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling of the hedgehog signaling pathway in human meningiomas.
  • Deregulation of the Hh pathway is involved in tumor development, since mutations in several components of this pathway were found in patients with basal cell carcinoma, medulloblastoma and other tumors; however, the role of Hh in meningiomas has not been studied yet.
  • Meningiomas represent 30% of primary cranial tumors, are mostly benign and prevail in the second half of life.
  • Novel therapies for meningiomas such as targeted molecular agents could use Hh pathway components.
  • To provide information concerning molecular alterations, by use of real-time RT-PCR, we studied expression at the mRNA level of 32 Hh pathway and target genes in 36 meningioma specimens of different grades. mRNA levels of 16 genes, involved mainly in Hh pathway activation and cell proliferation, increased in meningiomas in comparison with normal tissue, whereas those of 7 genes, mainly related to Hh pathway repression, decreased.
  • The most significant changes occurred in signal transduction (SMO) and GLI-transcription factor genes, and the target FOXM1 mRNA attained the highest values; their over-expression was found in aggressive and in benign tumors.
  • Some proliferation-related genes (SPP1, IGF2) were overexpressed in higher meningioma grades.
  • Our results show a marked activation of the Hh pathway in meningiomas, which may be important for their biological and clinical characterization and would be useful for gene therapy.
  • [MeSH-major] Biomarkers, Tumor / genetics. Hedgehog Proteins / genetics. Meningioma / genetics. RNA, Messenger / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 2004 May;122(5):1180-7 [15140221.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12561-6 [15314219.001]
  • [Cites] Cytogenet Cell Genet. 1996;72(4):297-8 [8641133.001]
  • [Cites] Dev Cell. 2005 Feb;8(2):143-51 [15736317.001]
  • [Cites] Development. 2005 Dec;132(23):5249-60 [16284117.001]
  • [Cites] Cancer Biol Ther. 2005 Oct;4(10):1050-4 [16258256.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 3;103(1):33-8 [16371461.001]
  • [Cites] Dev Biol. 2006 Feb 1;290(1):1-12 [16364285.001]
  • [Cites] Carcinogenesis. 2006 Jul;27(7):1334-40 [16501253.001]
  • [Cites] Curr Opin Cell Biol. 2007 Apr;19(2):159-65 [17303409.001]
  • [Cites] Int J Cancer. 2007 Sep 1;121(5):943-54 [17410535.001]
  • [Cites] Trends Cell Biol. 2007 Sep;17(9):438-47 [17845852.001]
  • [Cites] BMC Dev Biol. 2007;7:111 [17925019.001]
  • [Cites] Curr Biol. 2008 Mar 25;18(6):R238-41 [18364223.001]
  • [Cites] Curr Oncol Rep. 2008 Mar;10(2):107-13 [18377823.001]
  • [Cites] Int J Cancer. 2008 Jun 15;122(12):2707-18 [18381746.001]
  • [Cites] J Natl Cancer Inst. 2008 May 21;100(10):692-7 [18477794.001]
  • [Cites] Nat Rev Cancer. 2008 Jun;8(6):438-49 [18500245.001]
  • [Cites] J Biol Chem. 2008 Jul 25;283(30):20770-8 [18524773.001]
  • [Cites] Genes Dev. 2008 Sep 15;22(18):2454-72 [18794343.001]
  • [Cites] Cancer Res. 2008 Nov 1;68(21):8788-95 [18974121.001]
  • [Cites] Development. 2009 Mar;136(6):1029-38 [19234065.001]
  • [Cites] J Biol Chem. 2009 Aug 21;284(34):22888-97 [19556240.001]
  • [Cites] Neurobiol Dis. 2004 Apr;15(3):483-91 [15056455.001]
  • [Cites] Int J Cancer. 2003 Sep 20;106(5):758-65 [12866037.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2002;3:47-65 [12142354.001]
  • [Cites] J Biol Chem. 2002 Aug 23;277(34):30901-13 [12042312.001]
  • [Cites] Nature. 2002 May 16;417(6886):299-304 [12015606.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10139-49 [11741991.001]
  • [Cites] Dev Biol. 2001 Aug 1;236(1):30-45 [11456442.001]
  • [Cites] Nature. 2000 Aug 31;406(6799):1005-9 [10984056.001]
  • [Cites] N Engl J Med. 2009 Sep 17;361(12):1173-8 [19726761.001]
  • [Cites] N Engl J Med. 2009 Sep 17;361(12):1164-72 [19726763.001]
  • [Cites] N Engl J Med. 2009 Nov 19;361(21):2094-6 [19923581.001]
  • (PMID = 20386868.001).
  • [ISSN] 1528-3658
  • [Journal-full-title] Molecular medicine (Cambridge, Mass.)
  • [ISO-abbreviation] Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Hedgehog Proteins; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2896461
  •  go-up   go-down


52. Cheshier SH, Hanft SJ, Adler JR, Chang SD: CyberKnife radiosurgery for lesions of the foramen magnum. Technol Cancer Res Treat; 2007 Aug;6(4):329-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologies were determined either by prior surgery or radiographic criteria and included 25 benign tumors (nine meningiomas, five schwannomas, four neurofibromas, three hemangioblastomas, two ependymomas, one chordomas, and one pilocytic astrocytoma) along with 10 malignant growths (nine metastases and one chondrosarcoma).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17668941.001).
  • [ISSN] 1533-0346
  • [Journal-full-title] Technology in cancer research & treatment
  • [ISO-abbreviation] Technol. Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


53. Sentürk S, Oğuz KK, Cila A: Dynamic contrast-enhanced susceptibility-weighted perfusion imaging of intracranial tumors: a study using a 3T MR scanner. Diagn Interv Radiol; 2009 Mar;15(1):3-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To determine whether there are statistically significant differences in cerebral blood volume (CBV) and cerebral blood flow (CBF) of brain tumors of different histopathologic types including primary and secondary benign and malignant lesions.
  • To determine whether these measurements relate to tumor grade.
  • The Mann-Whitney U test was used to compare rCBV and rCBF measurements of tumor groups -- 13 low-grade and 13 high-grade neuroepithelial (NE) tumors, five metastases, 10 meningiomas, and four others.
  • Peritumoral rCBV and rCBF measurements of high grade NE tumors and metastases were also compared.
  • RESULTS: Measurements of rCBV and rCBF were statistically significantly higher (P < 0.05) in high-grade NE tumors than in low-grade NE tumors.
  • The difference was not statistically significant in comparing high-grade NE tumors with metastases and meningiomas.
  • Peritumoral rCBV of high-grade NE tumors was significantly higher than peritumoral rCBV of metastases (P < 0.05).

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19263367.001).
  • [ISSN] 1305-3612
  • [Journal-full-title] Diagnostic and interventional radiology (Ankara, Turkey)
  • [ISO-abbreviation] Diagn Interv Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


54. Shen Y, Nunes F, Stemmer-Rachamimov A, James M, Mohapatra G, Plotkin S, Betensky RA, Engler DA, Roy J, Ramesh V, Gusella JF: Genomic profiling distinguishes familial multiple and sporadic multiple meningiomas. BMC Med Genomics; 2009 Jul 09;2:42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic profiling distinguishes familial multiple and sporadic multiple meningiomas.
  • BACKGROUND: Meningiomas may occur either as familial tumors in two distinct disorders, familial multiple meningioma and neurofibromatosis 2 (NF2), or sporadically, as either single or multiple tumors in individuals with no family history.
  • Meningiomas in NF2 and approximately 60% of sporadic meningiomas involve inactivation of the NF2 locus, encoding the tumor suppressor merlin on chromosome 22q.
  • This study was undertaken to establish whether genomic profiling could distinguish familial multiple meningiomas from sporadic solitary and sporadic multiple meningiomas.
  • METHODS: We compared 73 meningiomas presenting as sporadic solitary (64), sporadic multiple (5) and familial multiple (4) tumors using genomic profiling by array comparative genomic hybridization (array CGH).
  • RESULTS: Sporadic solitary meningiomas revealed genomic rearrangements consistent with at least two mechanisms of tumor initiation, as unsupervised cluster analysis readily distinguished tumors with chromosome 22 deletion (associated with loss of the NF2 tumor suppressor) from those without chromosome 22 deletion.
  • Whereas sporadic meningiomas without chromosome 22 loss exhibited fewer chromosomal imbalance events overall, tumors with chromosome 22 deletion further clustered into two major groups that largely, though not perfectly, matched with their benign (WHO Grade I) or advanced (WHO Grades II and III) histological grade, with the latter exhibiting a significantly greater degree of genomic imbalance (P < 0.001).
  • Sporadic multiple meningiomas showed a frequency of genomic imbalance events comparable to the atypical grade solitary tumors.
  • By contrast, familial multiple meningiomas displayed no imbalances, supporting a distinct mechanism for the origin for these tumors.
  • CONCLUSION: Genomic profiling can provide an unbiased adjunct to traditional meningioma classification and provides a basis for exploring the different genetic underpinnings of tumor initiation and progression.
  • Most importantly, the striking difference observed between sporadic and familial multiple meningiomas indicates that genomic profiling can provide valuable information for differential diagnosis of subjects with multiple meningiomas and for considering the risk for tumor occurrence in their family members.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Pathol. 2009 Jul;19(3):409-20 [18637901.001]
  • [Cites] Brain Tumor Pathol. 2001;18(1):1-5 [11517968.001]
  • [Cites] J Neurosurg. 2000 Oct;93(2 Suppl):317-21 [11012068.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Neurology. 2000 Jan 11;54(1):71-6 [10636128.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2653-61 [15805262.001]
  • [Cites] Int J Cancer. 2005 Mar 20;114(2):249-56 [15540215.001]
  • [Cites] Brain Tumor Pathol. 2004;21(3):127-33 [15696974.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 21;101(51):17765-70 [15591353.001]
  • [Cites] Bioinformatics. 2004 Dec 12;20(18):3636-7 [15201182.001]
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • [Cites] Neurosurg Rev. 1997;20(2):117-23 [9226671.001]
  • [Cites] Neurosurgery. 1999 Aug;45(2):409-16 [10449091.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9212-7 [10430922.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6745-50 [10359783.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] J Neurosurg. 1998 Mar;88(3):562-9 [9488313.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] J Neurosurg. 1997 May;86(5):853-8 [9126902.001]
  • [Cites] Nat Genet. 1994 Feb;6(2):180-4 [8162072.001]
  • [Cites] Am J Pathol. 1995 Apr;146(4):827-32 [7717450.001]
  • [Cites] Neurology. 1993 Oct;43(10):2096-8 [8413972.001]
  • [Cites] Nature. 1993 Jun 10;363(6429):515-21 [8379998.001]
  • [Cites] Cell. 1993 Mar 12;72(5):791-800 [8453669.001]
  • [Cites] Q J Med. 1992 Aug;84(304):603-18 [1484939.001]
  • [Cites] J Neurol. 1992 Jul;239(6):343-4 [1512611.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1986 Apr;49(4):362-8 [3084711.001]
  • [Cites] Surg Neurol. 1989 Apr;31(4):255-60 [2928917.001]
  • [Cites] J Neurosurg. 1989 Jan;70(1):41-4 [2909686.001]
  • [Cites] Surg Neurol. 1987 Apr;27(4):319-22 [3824137.001]
  • [Cites] Neurology. 1990 Feb;40(2):312-4 [2300254.001]
  • [Cites] Neurosurgery. 1980 Sep;7(3):262-4 [6782502.001]
  • [Cites] Biostatistics. 2004 Oct;5(4):557-72 [15475419.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):9067-72 [15199222.001]
  • [Cites] Neurology. 2004 May 25;62(10):1904-5 [15159511.001]
  • [Cites] Eur J Hum Genet. 2008 Dec;16(12):1450-8 [18628790.001]
  • [Cites] Clin Neuropathol. 2008 Sep-Oct;27(5):334-45 [18808065.001]
  • [Cites] Curr Med Chem. 2008;15(8):826-33 [18393851.001]
  • [Cites] Semin Radiat Oncol. 2008 Apr;18(2):98-104 [18314064.001]
  • [Cites] Int J Cancer. 2008 Apr 15;122(8):1778-86 [18076069.001]
  • [Cites] Mol Cancer. 2007;6:64 [17937814.001]
  • [Cites] BMC Genomics. 2007;8:16 [17222329.001]
  • [Cites] Am J Clin Pathol. 2005 May;123(5):744-51 [15981814.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 May;65(5):445-54 [16772868.001]
  • [Cites] J Pathol. 2006 Mar;208(4):564-73 [16353169.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Oct 15;162(2):135-9 [16213361.001]
  • [Cites] Eur J Cancer. 2004 May;40(7):1082-94 [15093586.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5352-6 [14500367.001]
  • [Cites] Int J Cancer. 2003 Feb 10;103(4):483-8 [12478663.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):665-72 [12163391.001]
  • [Cites] Acta Neurol Belg. 2002 Jun;102(2):53-62 [12161900.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):114-23 [11150363.001]
  • (PMID = 19589153.001).
  • [ISSN] 1755-8794
  • [Journal-full-title] BMC medical genomics
  • [ISO-abbreviation] BMC Med Genomics
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / P01 NS024279
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2716362
  •  go-up   go-down


55. Asthagiri AR, Helm GA, Sheehan JP: Current concepts in management of meningiomas and schwannomas. Neurol Clin; 2007 Nov;25(4):1209-30, xi
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current concepts in management of meningiomas and schwannomas.
  • Meningiomas and schwannomas are the two most common extra-axial intracranial tumors in adults.
  • Since their initial discovery, these often-benign lesions have shared a parallel metamorphosis in their management.
  • [MeSH-major] Brain Neoplasms / therapy. Meningeal Neoplasms / therapy. Meningioma / therapy. Neurilemmoma / therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17964032.001).
  • [ISSN] 0733-8619
  • [Journal-full-title] Neurologic clinics
  • [ISO-abbreviation] Neurol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 126
  •  go-up   go-down


56. Jung TY, Jung S, Shin SR, Moon KS, Kim IY, Park SJ, Kang SS, Kim SH: Clinical and histopathological analysis of cystic meningiomas. J Clin Neurosci; 2005 Aug;12(6):651-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and histopathological analysis of cystic meningiomas.
  • Between 1993 and 2003, we treated 21 patients with cystic meningioma (of 365 with meningioma, 5.5%).
  • There were five atypical and 16 benign meningiomas on histopathology.
  • In type I and II cystic meningiomas, with intratumoral cysts, all cyst walls enhanced on MRI and had tumor cells in the cyst wall on histopathology.
  • In type III and IV cystic meningiomas, with peritumoral cysts, the cyst wall did not enhance on MRI and only one case (type III) had tumor cells in the cyst wall on histopathology.
  • [MeSH-major] Cysts / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16098756.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


57. Krayenbühl N, Pravdenkova S, Al-Mefty O: De novo versus transformed atypical and anaplastic meningiomas: comparisons of clinical course, cytogenetics, cytokinetics, and outcome. Neurosurgery; 2007 Sep;61(3):495-503; discussion 503-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] De novo versus transformed atypical and anaplastic meningiomas: comparisons of clinical course, cytogenetics, cytokinetics, and outcome.
  • OBJECTIVE: The clinical course of atypical and anaplastic meningiomas is heterogeneous.
  • As malignant gliomas, aggressive meningiomas may arise de novo or transform from a benign tumor.
  • This study aims to compare differences in clinical behavior, cytogenetics, cytokinetics, receptor status, and outcome between de novo malignant meningiomas and meningiomas that progressed to malignancy.
  • METHODS: Data from 36 patients with atypical or anaplastic meningiomas were selected for retrospective analysis and divided into two subgroups:.
  • 1) de novo atypical or anaplastic tumors and 2) tumors that progressed from a lower grade.
  • For meningiomas with progression, we calculated the interval between initial diagnosis and tumor progression.
  • RESULTS: For atypical meningiomas, the subgroups had significant differences in status of progesterone receptors, proliferative indices, cytogenetics, and patients' outcome.
  • These phenomena occurred mainly in patients with malignant transformation who had a worse outcome.
  • CONCLUSION: De novo malignant meningiomas and meningiomas with malignant transformation may represent distinct subgroups of atypical and anaplastic meningiomas.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Cytogenetic Analysis / methods. Meningioma / genetics. Meningioma / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17881961.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Patel R, Win H, Desai S, Patel K, Matthews JA, Acevedo-Duncan M: Involvement of PKC-iota in glioma proliferation. Cell Prolif; 2008 Feb;41(1):122-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, in vivo, the status and function of PKC-iota in human normal brain tissue, gliomas, benign and malignant meningiomas as well as its in vitro status in proliferating and confluent glioma cells, remains unknown.
  • OBJECTIVES: The objectives of our research were to determine whether expression of PKC-iota is altered either in gliomas or in benign and malignant meningiomas, compared to normal brain.
  • MATERIALS AND METHODS: Western blot analyses for PKC-iota were performed on 12 normal brain biopsies, 15 benign meningiomas, three malignant meningiomas and three gliomas.
  • In comparison, PKC-iota was robustly present in the majority of the benign meningiomas.
  • Similarly, PKC-iota was abundant in all malignant meningiomas and gliomas.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18211289.001).
  • [ISSN] 1365-2184
  • [Journal-full-title] Cell proliferation
  • [ISO-abbreviation] Cell Prolif.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Isoenzymes; 0 / RNA, Small Interfering; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.13 / protein kinase C lambda
  •  go-up   go-down


59. Wickremesekera A, Hovens CM, Kaye AH: Expression of ErbB-1 and ErbB-2 in meningioma. J Clin Neurosci; 2010 Sep;17(9):1155-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of ErbB-1 and ErbB-2 in meningioma.
  • Meningiomas are benign intracranial tumours treated by neurosurgical resection.
  • Effective molecular therapy for residual and recurrent meningiomas is currently unavailable.
  • We tested meningiomas for In-ErbB-1 and ErbB-2, and the levels were compared to normal brain, peripheral nerve, glioblastoma multiforme and vestibular schwannoma.
  • These preliminary results implicate a potential role for ErbB-2 in the benign tumourigenesis of meningioma consistent with the theoretical hierarchical interactions of homodimers of ErbB-2 that may be associated with low signal transduction.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Receptor, Epidermal Growth Factor / biosynthesis. Receptor, ErbB-2 / biosynthesis

  • Genetic Alliance. consumer health - Meningioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20547458.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


60. Dündar BN, Oktem F, Armağan A, Dündar NO, Bircan S, Yesildag A: Chronic renal failure and macrogenitalia associated with genitourinary neurofibromatosis. Pediatr Nephrol; 2010 Feb;25(2):353-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This disorder is characterized by the development of various tumors, including neurofibromas, neuroniomas, malignant and benign peripheral nerve sheath tumors, and meningiomas.

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • MedlinePlus Health Information. consumer health - Neurofibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain. 1988 Dec;111 ( Pt 6):1355-81 [3145091.001]
  • [Cites] Urology. 1992 Dec;40(6):555-6 [1466112.001]
  • [Cites] Am J Kidney Dis. 1990 Apr;15(4):357-60 [2108582.001]
  • [Cites] J Urol. 1967 Nov;98 (5):627-32 [6065518.001]
  • [Cites] JAMA. 1997 Jul 2;278(1):51-7 [9207339.001]
  • [Cites] Am J Surg Pathol. 1994 May;18(5):512-6 [8172325.001]
  • [Cites] Am J Med Genet. 1995 Jan 30;55(3):325-30 [7726231.001]
  • [Cites] Head Neck Surg. 1984 Mar-Apr;6(4):842-50 [6423572.001]
  • [Cites] Urology. 1997 Jun;49(6):960-2 [9187712.001]
  • [Cites] Cancer. 1970 Jun;25(6):1431-47 [4316326.001]
  • [Cites] J Urol. 1983 Dec;130(6):1176-9 [6417345.001]
  • [Cites] J Pediatr Surg. 2008 Nov;43(11):1998-2003 [18970931.001]
  • [Cites] Br J Urol. 1964 Dec;36:510-8 [14245890.001]
  • (PMID = 19826840.001).
  • [ISSN] 1432-198X
  • [Journal-full-title] Pediatric nephrology (Berlin, Germany)
  • [ISO-abbreviation] Pediatr. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


61. Soni CR, Kumar G, Sahota P, Miller DC, Litofsky NS: Metastases to Meckel's cave: report of two cases and comparative analysis of malignant tumors with meningioma and schwannoma of Meckel's cave. Clin Neurol Neurosurg; 2010 Dec;112(10):927-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastases to Meckel's cave: report of two cases and comparative analysis of malignant tumors with meningioma and schwannoma of Meckel's cave.
  • A comparative analysis of clinical features of malignant tumors of Meckel's cave with meningioma and schwannoma of Meckel's cave is discussed.
  • Our findings were then compared with well described case series of meningioma and schwannoma involving Meckel's cave.
  • 's [2] series of meningiomas involving Meckel's cave, 81% of patients presented with pain, 25% with paraesthesia, 63% with trigeminal sensory deficits and only 13% with trigeminal motor involvement.
  • Patients with malignant tumors were more likely to be older, and have paraesthesia in comparison with patients with meningioma.
  • CONCLUSION: Subtle clinical clues may help differentiate malignant from benign involvement of Meckel's cave.
  • [MeSH-major] Meningioma / secondary. Meningioma / surgery. Neurilemmoma / secondary. Neurilemmoma / surgery. Skull Base Neoplasms / secondary. Skull Base Neoplasms / surgery. Temporal Bone / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Schwannoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20728984.001).
  • [ISSN] 1872-6968
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


62. Caffo M, Caruso G, Galatioto S, Meli F, Cacciola F, Germanò A, Alafaci C, Tomasello F: Immunohistochemical study of the extracellular matrix proteins laminin, fibronectin and type IV collagen in secretory meningiomas. J Clin Neurosci; 2008 Jul;15(7):806-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical study of the extracellular matrix proteins laminin, fibronectin and type IV collagen in secretory meningiomas.
  • Secretory meningiomas are rare histological meningioma subtypes that have benign behavior, are highly vascularized and are frequently accompanied by massive peritumoral edema.
  • The aim of this study was to assess in secretory meningiomas the immunohistochemical expression of laminin, fibronectin and type IV collagen, proteins found in the extracellular matrix.
  • Extracellular matrix proteins were evaluated in samples from six secretory meningiomas using a semiquantitative scale ranging from not detected (0) to marked (3).
  • Meningiomas increase in size through increased production of extracellular matrix; furthermore, the proliferation of cells typically associated with neoplasia requires considerable interaction with the extracellular matrix.
  • [MeSH-major] Brain Neoplasms / metabolism. Extracellular Matrix / metabolism. Extracellular Matrix Proteins / metabolism. Meningioma / metabolism. Neoplasm Invasiveness / physiopathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18474427.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Collagen Type IV; 0 / Extracellular Matrix Proteins; 0 / Fibronectins; 0 / Laminin
  •  go-up   go-down


63. Strassner C, Buhl R, Mehdorn HM: Recurrence of intracranial meningiomas: did better methods of diagnosis and surgical treatment change the outcome in the last 30 years? Neurol Res; 2009 Jun;31(5):478-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence of intracranial meningiomas: did better methods of diagnosis and surgical treatment change the outcome in the last 30 years?
  • OBJECTIVE: Meningiomas are benign intracranial tumors growing from the arachnoid cap cells.
  • Although their behavior is usually benign, they tend to recur even after total removal, and their recurrence is dependent on different aspects.
  • METHODS: Between 1991 and 2002, 463 patients with an intracranial meningioma were operated in the Department of Neurosurgery, University of Kiel, Kiel, Germany.
  • We compared the outcome of these patients after operation and the different methods of radiation therapy and chemotherapy with the data from Buhl (1994), who analysed 661 patients with intracranial meningioma who were operated on in the Department of Neurosurgery, University of Essen, Essen, Germany, between 1968 and 1988, to find out whether better methods of diagnosis like magnetic resonance imaging scans, magnetic resonance spectroscopy, post-operative radiation therapy and chemotherapy have an influence on the recurrence and outcome after surgical treatment.
  • Both studies underlined the preponderance of female patients for intracranial meningiomas.
  • The intracranial localization of the meningiomas was similar to the distribution of the histological subtypes and the rate of recurrence; only the malignant meningiomas showed a higher grade of recurrence in the last study.
  • The outcome of the patients after surgical removal was improving in the last years; the 30 day post-operative mortality after a primary operation on an intracranial meningioma decreased from 12.1 to 3%.
  • After removal of a recurrent meningioma, the mortality declined from 20 to 12.5%.
  • CONCLUSION: In the last 30 years, nothing important changed at the time of appearance of meningiomas, concerning the gender distribution and localisation as well as histological subtypes.
  • With better operating modalities and additional treatment with radiation and gamma knife, the mortality decreased significantly from 12 to 3% and the outcome of the patients is still improving, so that even elderly patients with intracranial meningioma can undergo surgical treatment with minor risks.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / therapy. Meningioma / diagnosis. Meningioma / therapy

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19500450.001).
  • [ISSN] 0161-6412
  • [Journal-full-title] Neurological research
  • [ISO-abbreviation] Neurol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


64. Delgado-López PD, Martín-Velasco V, Castilla-Díez JM, Fernández-Arconada O, Corrales-García EM, Galacho-Harnero A, Rodríguez-Salazar A, Pérez-Mies B: Metastatic meningioma to the eleventh dorsal vertebral body: total en bloc spondylectomy. Case report and review of the literature. Neurocirugia (Astur); 2006 Jun;17(3):240-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic meningioma to the eleventh dorsal vertebral body: total en bloc spondylectomy. Case report and review of the literature.
  • INTRODUCTION: One in every thousand intracranial meningiomas metastatize extracranially.
  • To our knowledge, this is the first description of a total en bloc spondylectomy through a posterior approach for the treatment of an intraosseous metastatic meningioma to the eleventh dorsal vertebra.
  • CASE REPORT: In March 1996, a 37 year-old male underwent surgical resection for a left occipital intraventricular benign meningioma (WHO I).
  • Advice from a second pathologist was seeked, who suggested the diagnosis of intraosseous meningioma.
  • Definite pathology: benign meningioma (WHO I).
  • DISCUSSION: Distant metastases from intracranial meningiomas are rare entities, arising from benign lesions in, at least, 60% of cases.
  • Enam et al proposed a specific pathological score to differentiate benign, atypic and malignant meningiomas.
  • Such score correlates with the chance of metastatizing: more than 40% in malignant meningiomas compared to 3.8% of brain tumors overall.
  • [MeSH-major] Meningioma / pathology. Orthopedic Procedures / methods. Spinal Neoplasms / secondary. Spinal Neoplasms / surgery. Thoracic Vertebrae

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16855782.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


65. Zheng X, Liu W, Yang X, Gong J, Shen F, Shen G, Shen H, Zheng X, Fu W: Endoscope-assisted supraorbital keyhole approach for the resection of benign tumors of the sellar region. Minim Invasive Ther Allied Technol; 2007;16(6):363-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscope-assisted supraorbital keyhole approach for the resection of benign tumors of the sellar region.
  • The objective of the study was to evaluate the effectiveness of the supraorbital "keyhole" approach with endoscope assistance in surgical treatment of benign tumors around the sellar region.
  • Thirty-five patients, including 19 pituitary tumors, 11 craniopharyngiomas and five tuberculum sellae meningiomas, were enrolled in this study.
  • The supraorbital "keyhole" approach with endoscopic assistance in the surgical treatment of benign tumors around the sellar region is an ideal pattern.

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17852733.001).
  • [ISSN] 1364-5706
  • [Journal-full-title] Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy
  • [ISO-abbreviation] Minim Invasive Ther Allied Technol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


66. Asioli S, Senetta R, Maldi E, D'Ambrosio E, Satolli MA, Bussolati G, Cassoni P: "Benign" metastatic meningioma: clinico-pathological analysis of one case metastasising to the lung and overview on the concepts of either primitive or metastatic meningiomas of the lung. Virchows Arch; 2007 May;450(5):591-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "Benign" metastatic meningioma: clinico-pathological analysis of one case metastasising to the lung and overview on the concepts of either primitive or metastatic meningiomas of the lung.
  • Lung "metastases" of benign meningiomas are rarely described events of biological and clinical interest.
  • Anamnesis revealed that the patient underwent a surgical resection of cerebral meningioma 12 years before.
  • The morphological and immunohistochemical features of this lesion, together with the similarity with the original cerebral tumour and its indolent evolution, led to a final diagnosis of "benign" meningioma metastatic to the lung.
  • Lung metastatic meningiomas may be a diagnostic challenge because of their unusual site of presentation and the possible confusion with primitive lung meningiomas or primary mesenchymal lung lesions.
  • They represent a typical example of "benign" tumours that may implant to the lung similar to other tumours, definitely considered benign but reported to rarely present unusual secondary localization.
  • [MeSH-major] Brain Neoplasms / pathology. Lung Neoplasms / secondary. Meningioma / secondary

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1991 Mar 1;67(5):1412-7 [1991305.001]
  • [Cites] AJNR Am J Neuroradiol. 1987 Jan-Feb;8(1):127-30 [3101455.001]
  • [Cites] Virchows Arch. 2001 Aug;439(2):196-200 [11561761.001]
  • [Cites] Am J Surg Pathol. 1997 Aug;21(8):976 [9255263.001]
  • [Cites] J Neurosurg. 2003 Jan;98(1):194-8 [12546373.001]
  • [Cites] J Neurosurg. 1985 May;62(5):763-6 [3989597.001]
  • [Cites] Arch Pathol Lab Med. 1997 Jun;121(6):631-6 [9199633.001]
  • [Cites] Semin Diagn Pathol. 1995 May;12(2):193-206 [7638451.001]
  • [Cites] J Thorac Imaging. 2002 Jul;17 (3):227-9 [12082375.001]
  • [Cites] Clin Neurol Neurosurg. 1990;92(2):152-4 [2163798.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):207-14 [15043310.001]
  • [Cites] J Cutan Pathol. 1987 Jun;14(3):129-46 [3301927.001]
  • [Cites] Adv Clin Path. 2000 Jan;4(1):35-9 [10936897.001]
  • [Cites] Am J Surg Pathol. 1988 Mar;12(3):167-75 [2830799.001]
  • [Cites] J Laryngol Otol. 2004 Sep;118(9):724-6 [15509374.001]
  • [Cites] J Comput Assist Tomogr. 2001 Mar-Apr;25(2):311-3 [11242234.001]
  • [Cites] Neurosurgery. 1992 Dec;31(6):1113-6; discussion 1116 [1470323.001]
  • [Cites] Dtsch Med Wochenschr. 2004 Sep 3;129(36):1854-7 [15368156.001]
  • [Cites] Am J Clin Oncol. 2001 Dec;24(6):579-82 [11801758.001]
  • [Cites] Ann Thorac Surg. 1996 Jun;61(6):1823-4 [8651794.001]
  • [Cites] Hum Pathol. 1991 May;22(5):469-74 [1709609.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999 Aug;88(2):170-6 [10468461.001]
  • [Cites] Neurosurgery. 1987 May;20(5):688-94 [3601014.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):453-60 [9130993.001]
  • [Cites] Clin Orthop Relat Res. 1988 Dec;(237):275-85 [3056645.001]
  • [Cites] Hum Pathol. 1999 Apr;30(4):425-9 [10208464.001]
  • [Cites] Surg Neurol. 1988 May;29(5):410-3 [3363477.001]
  • [Cites] Jpn J Clin Oncol. 2003 Feb;33(2):86-8 [12629059.001]
  • (PMID = 17431673.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


67. Couldwell WT, Cole CD, Al-Mefty O: Patterns of skull base meningioma progression after failed radiosurgery. J Neurosurg; 2007 Jan;106(1):30-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of skull base meningioma progression after failed radiosurgery.
  • OBJECT: Stereotactic radiosurgery has been reported to be an effective alternative to surgical removal of small to medium benign meningiomas as well as an adjuvant treatment modality to reduce the risk of tumor progression after subtotal resection.
  • Little is known, however, regarding the growth patterns of meningiomas that fail to stabilize after radiosurgery.
  • METHODS: The authors report 13 cases of benign skull base meningiomas (World Health Organization Grade I) that demonstrated progression after radiosurgical treatment as a primary or an adjuvant therapy.
  • CONCLUSIONS: Skull base meningioma growth can be aggressive after failed radiosurgery in some patients, and treatment failure can occur at long intervals following treatment.
  • Special attention must be devoted to such significant occurrences given the increasing number of patients undergoing stereotactic radiosurgery for benign tumors, and careful extended (> 10 years) follow up must be undertaken in all patients after radiosurgery.
  • [MeSH-major] Meningioma / pathology. Meningioma / surgery. Radiosurgery. Skull Base Neoplasms / pathology. Skull Base Neoplasms / surgery

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17236485.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Karwacki MW, Woźniak W: [Neurofibromatosis--an inborn genetic disorder with susceptibility to neoplasia]. Med Wieku Rozwoj; 2006 Jul-Sep;10(3 Pt 2):923-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nf-2 is a multisystem genetic disorder associated with bilateral vestibular schwannomas, spinal cord schwannomas, meningiomas, gliomas, and juvenile cataracts with a paucity of cutaneous features, which are seen more consistently in Nf-1.
  • Optic gliomas and both malignant and benign peripheral nerve sheet tumours are the most common malignancies arising in Nf-1 patients.


69. Rosenberg E, Sheiner E, Holcberg G: Neurofibromatosis type 1 and masses of the appendix: a case report. J Reprod Med; 2006 Jul;51(7):578-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas and other benign central nervous system tumors, such as ependymomas, are common features.


70. Marosi C, Hassler M, Roessler K, Reni M, Sant M, Mazza E, Vecht C: Meningioma. Crit Rev Oncol Hematol; 2008 Aug;67(2):153-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningioma.
  • Meningiomas are mostly benign tumours originating from the arachnoid cap cells, represent 13-26% of all intracranial tumours.
  • Five-year survival for typical meningiomas exceeds 80%, but is poorer (5-year survival <60%) in malignant and atypical meningiomas.
  • Radiotherapy is currently used in the clinical practice in atypical, malignant or recurrent meningioma at a total dose of 45-60Gy.
  • Radiosurgery has gained more and more importance in the management of meningiomas, especially in meningiomas that cannot be completely resected as for many skull base meningiomas.
  • [MeSH-major] Meningeal Neoplasms / therapy. Meningioma / therapy

  • Genetic Alliance. consumer health - Meningioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18342535.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 184
  •  go-up   go-down


71. Gerber MA, Bahr SM, Gutmann DH: Protein 4.1B/differentially expressed in adenocarcinoma of the lung-1 functions as a growth suppressor in meningioma cells by activating Rac1-dependent c-Jun-NH(2)-kinase signaling. Cancer Res; 2006 May 15;66(10):5295-303
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein 4.1B/differentially expressed in adenocarcinoma of the lung-1 functions as a growth suppressor in meningioma cells by activating Rac1-dependent c-Jun-NH(2)-kinase signaling.
  • Meningiomas are the second most common brain tumor in adults, yet comparatively little is presently known about the dysregulated growth control pathways involved in their formation and progression.
  • One of the most frequently observed genetic changes in benign meningioma involves loss of protein 4.1B expression.
  • Previous studies from our laboratory have shown that protein 4.1B growth suppression in meningioma is associated with the activation of the c-Jun-NH(2)-kinase (JNK) pathway and requires localization of a small unique region (U2 domain) of protein 4.1B to the plasma membrane.
  • In this report, we show that protein 4.1B/differentially expressed in adenocarcinoma of the lung-1 (DAL-1) expression in meningioma cells in vitro results in JNK activation, which requires the sequential activation of Src, Rac1, and JNK.
  • Last, protein 4.1B/DAL-1 regulation of this critical growth control pathway in meningioma cells requires the presence of the U2 domain.
  • Collectively, these observations provide the first mechanistic insights into the function of protein 4.1B as a growth regulator in meningioma cells.
  • [MeSH-major] JNK Mitogen-Activated Protein Kinases / metabolism. Membrane Proteins / metabolism. Meningioma / enzymology. Meningioma / pathology. Tumor Suppressor Proteins / metabolism. rac1 GTP-Binding Protein / metabolism

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16707455.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin A; 0 / EPB41L3 protein, human; 0 / Membrane Proteins; 0 / Microfilament Proteins; 0 / RAC1 protein, human; 0 / Retinoblastoma Protein; 0 / Tumor Suppressor Proteins; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; EC 2.7.11.25 / MAP Kinase Kinase Kinases; EC 2.7.11.25 / mitogen-activated protein kinase kinase kinase 11; EC 3.6.5.2 / rac1 GTP-Binding Protein
  •  go-up   go-down


72. Kwon Y, Bae JS, Kim JM, Lee DH, Kim SY, Ahn JS, Kim JH, Kim CJ, Kwun BD, Lee JK: Visual changes after gamma knife surgery for optic nerve tumors. Report of three cases. J Neurosurg; 2005 Jan;102 Suppl:143-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumors involving the optic nerve (optic glioma, optic nerve sheath meningioma) are benign but difficult to treat.
  • [MeSH-major] Cranial Nerve Neoplasms / surgery. Exophthalmos / etiology. Meningeal Neoplasms / surgery. Meningioma / surgery. Optic Nerve Glioma / surgery. Optic Nerve Neoplasms / surgery. Postoperative Complications. Radiosurgery / instrumentation. Vision Disorders / etiology

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Vision Impairment and Blindness.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15662798.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Lah TT, Nanni I, Trinkaus M, Metellus P, Dussert C, De Ridder L, Rajcević U, Blejec A, Martin PM: Toward understanding recurrent meningioma: the potential role of lysosomal cysteine proteases and their inhibitors. J Neurosurg; 2010 May;112(5):940-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toward understanding recurrent meningioma: the potential role of lysosomal cysteine proteases and their inhibitors.
  • OBJECT: The first aim of this study was to diagnose more aggressive and potentially recurrent meningiomas using an in vitro embryonic chick heart invasiveness assay in which lysosomal enzyme cathepsin B was used as the invasiveness marker.
  • The second aim was to confirm if cathepsin B and/or cathepsin L and their endogenous inhibitors were also prognostic parameters in the clinical study of 119 patients with meningioma.
  • METHODS: Primary meningioma cultured spheroids were "confronted" with embryonic chick heart spheroids in vitro, and cathepsin B was used as molecular marker to immunolabel the invasive tumor cells.
  • In vitro invasion assays of the malignant meningioma cells were used to assess the invasive potential related to the cysteine cathepsins.
  • As to the second aim, the possible association of cathepsin B along with selected molecular markers, cathepsin L, and endogenous cysteine protease inhibitors (stefins A and B and cystatin C) with meningioma malignancy was determined using enzyme-linked immunosorbent assays in tumor homogenates.
  • Univariate and multivariate analyses were used to compare these parameters with established biological markers of meningioma recurrence in 119 patients with meningiomas.
  • RESULTS: The more invasive tumors, which characteristically overgrew the normal tissue, were identified even within a group of histologically benign meningiomas.
  • Matrigel invasion of malignant meningioma cells was significantly altered by modulating cathepsin B activity and by stefin B silencing.
  • In the clinical samples of meningioma, the levels of cathepsins B and L, stefin B, and cystatin C were highest in the tumors of higher histological grades, whereas stefin A and progesterone receptor were the only markers that were significantly increased and decreased, respectively, in WHO Grade III lesions.
  • As expected, WHO grade, age, and Simpson grade (complete tumor resection) were prognostic, with Simpson grade only relevant in the short term (up to 90 months) but not in longer-term follow-up.
  • CONCLUSIONS: The data indicate that the cysteine cathepsins and their inhibitors are involved in a process related to early meningioma recurrence, regardless of their histological classification.
  • Of note, the known tumor invasiveness marker cathepsin B, measured in whole-tumor homogenates, was not prognostic, in contrast to its endogenous inhibitor stefin B, which was highly significant and the only independent prognostic factor to predict meningioma relapse in multivariate analysis and reported herein for the first time.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / pathology. Cysteine Proteinase Inhibitors / pharmacology. Cysteine Proteinase Inhibitors / therapeutic use. Lysosomes / drug effects. Meningioma / drug therapy. Meningioma / pathology


74. Caffo M, Caruso G, Germanò A, Galatioto S, Meli F, Tomasello F: CD68 and CR3/43 immunohistochemical expression in secretory meningiomas. Neurosurgery; 2005 Sep;57(3):551-7; discussion 551-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD68 and CR3/43 immunohistochemical expression in secretory meningiomas.
  • OBJECTIVE: Secretory meningiomas (SMs) are unusual benign meningiomas.
  • CONCLUSION: Macrophage infiltration and major histocompatibility complex Class II immunoreactivity in this subtype of meningioma suggest the occurrence of an immune response in the presence of SM.
  • [MeSH-major] Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Brain Neoplasms / metabolism. Immunohistochemistry / methods. Macrophage-1 Antigen / metabolism. Meningioma / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16145535.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / Macrophage-1 Antigen
  •  go-up   go-down


75. Schiestel C, Ryan D: Quality of life in patients with meningiomas: the true meaning of "benign". Front Biosci (Elite Ed); 2009;1:488-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life in patients with meningiomas: the true meaning of "benign".
  • Even the limited available literature makes it clear that the course of treatment of patients with meningiomas can be anything but benign.
  • This article provides a review of current research on QOL related to the surgical treatment of meningiomas to help increase clinicians' understanding of the complex nature of QOL assessment and how this assessment can be applied to neurosurgical patients.
  • [MeSH-major] Health Status Indicators. Meningioma / psychology. Psychometrics / methods. Quality of Life / psychology. Surveys and Questionnaires

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19482662.001).
  • [ISSN] 1945-0508
  • [Journal-full-title] Frontiers in bioscience (Elite edition)
  • [ISO-abbreviation] Front Biosci (Elite Ed)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down


76. Ildan F, Erman T, Göçer AI, Tuna M, Bağdatoğlu H, Cetinalp E, Burgut R: Predicting the probability of meningioma recurrence in the preoperative and early postoperative period: a multivariate analysis in the midterm follow-up. Skull Base; 2007 May;17(3):157-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predicting the probability of meningioma recurrence in the preoperative and early postoperative period: a multivariate analysis in the midterm follow-up.
  • We reviewed the clinical, radiological, surgical, and histopathological features of patients with meningiomas to identify factors that can predict tumor recurrence after "microscopic total removal," to improve preoperative surgical planning, and to help determine the need for close radiological observation at shorter intervals or the need for radiotherapy as an adjuvant treatment in the early postoperative period.
  • Clinical data, magnetic resonance imaging studies, angiographic data, operative reports, and histopathological findings were examined retrospectively in 137 patients with a meningioma treated microsurgically and with no evidence of residual tumor on postoperative MR images.
  • However, age, gender, location of tumor, dural tail, calcification, signal intensity on T1-weighted images, and histopathologic subtypes in the benign group were not significant predictors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1999 Mar;90(3):455-62 [10067913.001]
  • [Cites] J Neurosurg. 1999 Sep;91(3):384-90 [10470811.001]
  • [Cites] Neurosurgery. 2001 Nov;49(5):1046-51; discussion 1051-2 [11846896.001]
  • [Cites] Neurosurgery. 1992 Dec;31(6):1015-21; discussion 1021-2 [1281915.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Neurosurgery. 1992 Jun;30(6):932-5 [1614599.001]
  • [Cites] Neurosurgery. 1992 Jul;31(1):2-12 [1641106.001]
  • [Cites] Semin Ultrasound CT MR. 1992 Jun;13(3):154-69 [1642904.001]
  • [Cites] J Comput Assist Tomogr. 1991 Jan-Feb;15(1):45-51 [1987201.001]
  • [Cites] Radiology. 1990 May;175(2):431-3 [2326470.001]
  • [Cites] Acta Neurochir (Wien). 1989;100(3-4):104-7 [2589115.001]
  • [Cites] J Neurosurg. 1989 Sep;71(3):347-51 [2769385.001]
  • [Cites] Radiology. 1989 Mar;170(3 Pt 1):857-62 [2916043.001]
  • [Cites] Acta Neurochir (Wien). 1988;95(1-2):3-5 [3218552.001]
  • [Cites] Neurosurgery. 1978 Sep-Oct;3(2):219-25 [360097.001]
  • [Cites] Neurosurgery. 1987 May;20(5):688-94 [3601014.001]
  • [Cites] Surg Neurol. 1986 Nov;26(5):461-9 [3764651.001]
  • [Cites] J Neurosurg. 1986 Jan;64(1):58-63 [3941351.001]
  • [Cites] Surg Neurol. 1986 Mar;25(3):233-42 [3945904.001]
  • [Cites] Surg Neurol. 1986 May;25(5):436-40 [3961659.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] Surg Neurol. 1985 Aug;24(2):165-72 [4012573.001]
  • [Cites] J Neurosurg Sci. 1985 Jan-Mar;29(1):11-7 [4067631.001]
  • [Cites] Acta Neuropathol. 1983;61(2):130-4 [6637397.001]
  • [Cites] AJNR Am J Neuroradiol. 1982 May-Jun;3(3):267-76 [6805276.001]
  • [Cites] J Neurosurg. 1983 Jan;58(1):51-6 [6847909.001]
  • [Cites] Neurol Med Chir (Tokyo). 1995 May;35(5):289-93 [7623949.001]
  • [Cites] J Neurosurg. 1995 Jan;82(1):17-27 [7815129.001]
  • [Cites] Acta Neurochir Suppl (Wien). 1994;60:369-72 [7976592.001]
  • [Cites] Acta Neurochir (Wien). 1994;126(2-4):53-8 [8042555.001]
  • [Cites] Am J Surg Pathol. 1993 Mar;17(3):239-47 [8434704.001]
  • [Cites] Radiology. 1977 May;123(2):375-7 [847205.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(6):763-70 [8836295.001]
  • [Cites] J Neurosurg. 1997 May;86(5):793-800 [9126894.001]
  • [Cites] J Neurosurg. 1997 Sep;87(3):368-73 [9285600.001]
  • [Cites] Surg Neurol. 1997 Dec;48(6):584-90; discussion 590-1 [9400640.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1455-65 [9414189.001]
  • [Cites] Acta Neurochir (Wien). 1997;139(12):1136-42 [9479419.001]
  • [Cites] Neurosurgery. 1998 Mar;42(3):476-80 [9526980.001]
  • (PMID = 17973029.001).
  • [ISSN] 1531-5010
  • [Journal-full-title] Skull base : official journal of North American Skull Base Society ... [et al.]
  • [ISO-abbreviation] Skull Base
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1888737
  •  go-up   go-down


77. Saydam O, Shen Y, Würdinger T, Senol O, Boke E, James MF, Tannous BA, Stemmer-Rachamimov AO, Yi M, Stephens RM, Fraefel C, Gusella JF, Krichevsky AM, Breakefield XO: Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway. Mol Cell Biol; 2009 Nov;29(21):5923-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway.
  • Meningiomas, one of the most common human brain tumors, are derived from arachnoidal cells associated with brain meninges, are usually benign, and are frequently associated with neurofibromatosis type 2.
  • Here, we define a typical human meningioma microRNA (miRNA) profile and characterize the effects of one downregulated miRNA, miR-200a, on tumor growth.
  • Elevated levels of miR-200a inhibited meningioma cell growth in culture and in a tumor model in vivo.
  • Downregulation of miR-200a in meningiomas and arachnoidal cells resulted in increased expression of beta-catenin and cyclin D1 involved in cell proliferation. miR-200a was found to directly target beta-catenin mRNA, thereby inhibiting its translation and blocking Wnt/beta-catenin signaling, which is frequently involved in cancer.
  • A direct correlation was found between the downregulation of miR-200a and the upregulation of beta-catenin in human meningioma samples.
  • Thus, miR-200a appears to act as a multifunctional tumor suppressor miRNA in meningiomas through effects on the E-cadherin and Wnt/beta-catenin signaling pathways.
  • This reveals a previously unrecognized signaling cascade involved in meningioma tumor development and highlights a novel molecular interaction between miR-200a and Wnt signaling, thereby providing insights into novel therapies for meningiomas.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Cell Biol. 2008 Apr;20(2):119-25 [18339531.001]
  • [Cites] Genes Dev. 2008 Apr 1;22(7):894-907 [18381893.001]
  • [Cites] J Biol Chem. 2008 May 30;283(22):14910-4 [18411277.001]
  • [Cites] EMBO Rep. 2008 Jun;9(6):582-9 [18483486.001]
  • [Cites] Cancer Res. 2008 Jul 15;68(14):5795-802 [18632633.001]
  • [Cites] Curr Mol Med. 2008 Sep;8(6):446-58 [18781952.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17967-72 [19004799.001]
  • [Cites] Oncogene. 2008 Nov 24;27(55):6920-9 [19029934.001]
  • [Cites] Science. 2000 Mar 3;287(5458):1606-9 [10733430.001]
  • [Cites] Genes Dev. 2000 Aug 1;14(15):1837-51 [10921899.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):218-21 [11668501.001]
  • [Cites] Science. 2002 May 31;296(5573):1644-6 [12040179.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] RNA. 2003 Oct;9(10):1274-81 [13130141.001]
  • [Cites] Nat Rev Genet. 2004 Sep;5(9):691-701 [15372092.001]
  • [Cites] Nature. 2004 Sep 16;431(7006):350-5 [15372042.001]
  • [Cites] Ann N Y Acad Sci. 1991;615:338-43 [2039155.001]
  • [Cites] Cancer Res. 1992 Apr 1;52(7):1981-7 [1551127.001]
  • [Cites] Cell. 1993 Mar 12;72(5):791-800 [8453669.001]
  • [Cites] Nature. 1993 Jun 10;363(6429):515-21 [8379998.001]
  • [Cites] Brain Pathol. 1990 Sep;1(1):33-40 [1669691.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4696-701 [7553651.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] Oncogene. 1999 Apr 1;18(13):2231-9 [10327069.001]
  • [Cites] Nature. 2004 Nov 11;432(7014):231-5 [15531879.001]
  • [Cites] Mol Ther. 2005 Mar;11(3):435-43 [15727940.001]
  • [Cites] Nucleic Acids Res. 2005;33(4):1290-7 [15741182.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5070-5 [15958550.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6029-33 [16024602.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Oct 15;162(2):135-9 [16213361.001]
  • [Cites] Mol Ther. 2005 Nov;12(5):803-12 [16112910.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 [16461460.001]
  • [Cites] BMC Bioinformatics. 2006;7:30 [16423281.001]
  • [Cites] Novartis Found Symp. 2005;271:179-87; discussion 187-90, 198-9 [16605135.001]
  • [Cites] Histopathology. 2006 Aug;49(2):178-87 [16879395.001]
  • [Cites] BMC Bioinformatics. 2006;7:411 [16978421.001]
  • [Cites] PLoS One. 2007;2(6):e571 [17593970.001]
  • [Cites] Gastroenterology. 2007 Aug;133(2):647-58 [17681183.001]
  • [Cites] Nature. 2007 Oct 11;449(7163):682-8 [17898713.001]
  • [Cites] Neurobiol Dis. 2008 Feb;29(2):278-92 [17962031.001]
  • [Cites] Clin Chem. 2007 Dec;53(12):2051-9 [17901113.001]
  • [Cites] World J Gastroenterol. 2008 Mar 28;14(12):1823-7 [18350618.001]
  • [Cites] Nat Cell Biol. 2008 May;10(5):593-601 [18376396.001]
  • (PMID = 19703993.001).
  • [ISSN] 1098-5549
  • [Journal-full-title] Molecular and cellular biology
  • [ISO-abbreviation] Mol. Cell. Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA069246; United States / NCI NIH HHS / CA / P50 CA086355; United States / NCI NIH HHS / CA / CA86355; United States / NINDS NIH HHS / NS / P01 NS024279; United States / NINDS NIH HHS / NS / NS24279; United States / NCI NIH HHS / CA / CA69246
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins; 0 / MicroRNAs; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Wnt Proteins; 0 / beta Catenin; 136601-57-5 / Cyclin D1
  • [Other-IDs] NLM/ PMC2772747
  •  go-up   go-down


78. Aruga J, Nozaki Y, Hatayama M, Odaka YS, Yokota N: Expression of ZIC family genes in meningiomas and other brain tumors. BMC Cancer; 2010;10:79
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of ZIC family genes in meningiomas and other brain tumors.
  • Although human ZIC genes are known to be molecular markers for medulloblastomas, their expression in meningioma has not been addressed to date.
  • METHODS: We examined the mRNA and protein expression of human ZIC1, ZIC2, ZIC3, ZIC4 and ZIC5 genes in meningiomas in comparison to other brain tumors, using RT-PCR, analysis of published microarray data, and immunostaining.
  • RESULTS: ZIC1, ZIC2 and ZIC5 transcript levels in meningiomas were higher than those in whole brain or normal dura mater, whereas all five ZIC genes were abundantly expressed in medulloblastomas.
  • The expression level of ZIC1 in public microarray data was greater in meningiomas classified as World Health Organization Grade II (atypical) than those classified as Grade I (benign).
  • Immunoscreening using anti-ZIC antibodies revealed that 23 out of 23 meningioma cases were ZIC1/2/3/5-immunopositive.
  • By comparison, nuclear staining by the anti-ZIC4 antibody was not observed in any meningioma case, but was strongly detected in all four medulloblastomas.
  • ZIC-positive meningiomas included meningothelial, fibrous, transitional, and psammomatous histological subtypes.
  • CONCLUSIONS: ZIC1, ZIC2, and ZIC5 are novel molecular markers for meningiomas whereas ZIC4 expression is highly selective for medulloblastomas.
  • [MeSH-major] Brain Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Meningioma / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurg Focus. 2007;23(4):E3 [17961040.001]
  • [Cites] Dev Biol. 2007 Jun 15;306(2):669-84 [17490632.001]
  • [Cites] Physiol Genomics. 1999 Aug 31;1(2):83-91 [11015565.001]
  • [Cites] J Neurosci. 2002 Jan 1;22(1):218-25 [11756505.001]
  • [Cites] Neurology. 2002 Dec 24;59(12):1985-7 [12499499.001]
  • [Cites] Mol Cell Neurosci. 2004 Jun;26(2):205-21 [15207846.001]
  • [Cites] Cancer Res. 1996 Jan 15;56(2):377-83 [8542595.001]
  • [Cites] Clin Genet. 2005 Apr;67(4):290-6 [15733262.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2575-83 [15880380.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • [Cites] Nucleic Acids Res. 2007;35(7):e51 [17344319.001]
  • [Cites] J Neuroimmunol. 2008 Sep 15;201-202:163-5 [18639938.001]
  • [Cites] Int J Cancer. 2009 Jan 15;124(2):346-51 [19003955.001]
  • [Cites] J Neurol. 2010 Apr;257(4):509-17 [20035430.001]
  • [Cites] J Neurosci. 2008 Apr 30;28(18):4712-25 [18448648.001]
  • (PMID = 20199689.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / Vimentin; 0 / ZIC1 protein, human; 0 / ZIC2 protein, human; 0 / ZIC5 protein, human
  • [Other-IDs] NLM/ PMC2838823
  •  go-up   go-down


79. Fogliata A, Clivio A, Nicolini G, Vanetti E, Cozzi L: Intensity modulation with photons for benign intracranial tumours: a planning comparison of volumetric single arc, helical arc and fixed gantry techniques. Radiother Oncol; 2008 Dec;89(3):254-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity modulation with photons for benign intracranial tumours: a planning comparison of volumetric single arc, helical arc and fixed gantry techniques.
  • BACKGROUND AND PURPOSE: The potential benefits and limitations of the new RapidArc treatment concept compared to Helical Tomotherapy and fixed gantry intensity modulation techniques have been assessed at treatment planning level on 12 patients presenting with 'benign' brain tumours.
  • MATERIALS AND METHODS: Plans for five acoustic neurinomas, five meningiomas and two pituitary adenomas were computed for an Helical Tomotherapy (HT) unit, for RapidArc delivery (RA) on a linac equipped with two types of MLC (RA_HD120 with the new High Definition MLC with 2.5mm leaf width at isocentre and RA_M120 with the standard Millennium with 5mm resolution) and for fixed beam IMRT with the High Definition MLC.
  • [MeSH-major] Adenoma / radiotherapy. Brain Neoplasms / radiotherapy. Meningioma / radiotherapy. Neuroma, Acoustic / radiotherapy. Pituitary Neoplasms / radiotherapy. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Intensity-Modulated / methods

  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18760851.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


80. Utsuki S, Oka H, Sato Y, Kawano N, Tsuchiya B, Kobayashi I, Fujii K: Invasive meningioma is associated with a low expression of E-cadherin and beta-catenin. Clin Neuropathol; 2005 Jan-Feb;24(1):8-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive meningioma is associated with a low expression of E-cadherin and beta-catenin.
  • Invasive meningioma shows benign histological features (WHO grade 1) and the brain expansion at the tumor-brain interface, and recurs more frequently than common meningiomas.
  • To determine the mechanism of brain expansion, we studied the relationship between invasive meningioma and cell adhesion molecules.
  • Immunostaining for E-cadherin (E-CH), N-cadherin (N-CH), beta-catenin, and Ki-67 was performed in 103 meningiomas that consisted of 61 meningothelial meningiomas, 25 fibrous meningiomas, 12 invasive meningiomas and 5 anaplastic meningiomas.
  • All the 61 meningothelial meningiomas, 10 of 12 invasive meningiomas, and 3 of 5 anaplastic meningiomas were positive for both E-CH and beta-catenin, while these were both negative in all of the fibrous meningiomas.
  • In invasive meningiomas, the expansive part of the tumor showed a lower rate (4/12 tumors) of E-CH and beta-catenin positivity, while the central part showed a higher rate (10/12 tumors).
  • The Ki-67 labeling index was higher in invasive and anaplastic meningiomas than in meningothelial meningiomas.
  • These results suggest that a reduction in cell adhesion molecules and increased proliferative activity may be related, which may lead to a better understanding of the mechanism of meningioma expansion in the future.
  • [MeSH-major] Cadherins / metabolism. Cytoskeletal Proteins / metabolism. Meningeal Neoplasms / metabolism. Meningeal Neoplasms / pathology. Meningioma / metabolism. Meningioma / pathology. Trans-Activators / metabolism

  • Genetic Alliance. consumer health - Meningioma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15696778.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / Cadherins; 0 / Cytoskeletal Proteins; 0 / Ki-67 Antigen; 0 / Trans-Activators; 0 / beta Catenin
  •  go-up   go-down


81. Gerszten PC, Novotny J Jr, Quader M, Dewald VC, Flickinger JC: Prospective evaluation of a dedicated spine radiosurgery program using the Elekta Synergy S system. J Neurosurg; 2010 Dec;113 Suppl:236-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common benign tumors (30 cases total) included 10 schwannomas, 5 neurofibromas, and 5 meningiomas.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21121807.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Rao G, Klimo P Jr, Jensen RL, MacDonald JD, Couldwell WT: Surgical strategies for recurrent craniofacial meningiomas. Neurosurgery; 2006 May;58(5):874-80; discussion 874-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical strategies for recurrent craniofacial meningiomas.
  • OBJECTIVE: Recurrent cranial base meningiomas are among the most difficult tumors to treat surgically.
  • Although they are histologically benign, these tumors often invade through the cranial base into the infratemporal and pterygopalatine fossae.
  • METHODS: Between 2000 and 2004, seven patients with meningiomas recurring through the cranial base into facial structures were treated at the University of Utah.
  • CONCLUSION: Meningiomas that recur into facial structures present a unique treatment challenge.
  • [MeSH-major] Facial Neoplasms / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Neoplasm Recurrence, Local / surgery. Skull Base Neoplasms / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16639321.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Rogers L, Jensen R, Perry A: Chasing your dural tail: Factors predicting local tumor control after gamma knife stereotactic radiosurgery for benign intracranial meningiomas: In regard to DiBiase et al. (Int J Radiat Oncol Biol Phys 2004;60:1515-1519). Int J Radiat Oncol Biol Phys; 2005 Jun 1;62(2):616-8; author reply 618-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chasing your dural tail: Factors predicting local tumor control after gamma knife stereotactic radiosurgery for benign intracranial meningiomas: In regard to DiBiase et al. (Int J Radiat Oncol Biol Phys 2004;60:1515-1519).
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Radiosurgery / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1515-9 [15590183.001]
  • (PMID = 15890610.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


84. Lee DJ, Maseyesva B, Westra W, Long D, Niparko JK, Califano J: Microsatellite analysis of recurrent vestibular schwannoma (acoustic neuroma) following stereotactic radiosurgery. Otol Neurotol; 2006 Feb;27(2):213-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Deletions on chromosome 10 are seen in both benign and higher-grade meningiomas and intracranial malignancies associated with radiotherapy.

  • Genetic Alliance. consumer health - Acoustic Neuroma.
  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16436992.001).
  • [ISSN] 1531-7129
  • [Journal-full-title] Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
  • [ISO-abbreviation] Otol. Neurotol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Neurofibromin 2
  •  go-up   go-down


85. Iwai Y, Yamanaka K, Ikeda H: Gamma Knife radiosurgery for skull base meningioma: long-term results of low-dose treatment. J Neurosurg; 2008 Nov;109(5):804-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma Knife radiosurgery for skull base meningioma: long-term results of low-dose treatment.
  • OBJECT: In this study, the authors evaluate the long-term results after Gamma Knife radiosurgery of cranial base meningiomas.
  • METHODS: Between January 1994 and December 2001, the authors treated benign cranial base meningiomas in 108 patients using low-dose Gamma Knife radiosurgery.
  • CONCLUSIONS: Gamma Knife radiosurgery is a safe and effective treatment for cranial base meningiomas as demonstrated with a long-term follow-up period of > 7 years.
  • Surgeons must be aware of the possibility of treatment failure, defined as local failure, marginal failure, and malignant transformation; however, this may be the natural course of meningiomas and not related to radiosurgery.
  • [MeSH-major] Meningioma / surgery. Radiosurgery / methods. Skull Base Neoplasms / surgery

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18976068.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Fèvre-Montange M, Champier J, Durand A, Wierinckx A, Honnorat J, Guyotat J, Jouvet A: Microarray gene expression profiling in meningiomas: differential expression according to grade or histopathological subtype. Int J Oncol; 2009 Dec;35(6):1395-407
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microarray gene expression profiling in meningiomas: differential expression according to grade or histopathological subtype.
  • Meningiomas, one of the largest subgroup of intracranial tumours are generally benign, but can progress to malignancy.
  • They are classified into the three World Health Organization grades: benign, atypical and anaplastic meningiomas.
  • We have performed a microarray transcriptomic study on 17 meningiomas of different malignancy using CodeLink Uniset Human Whole Genome Bioarrays to try to distinguish the different grades and histopathological subtypes.
  • Unsupervised hierarchical clustering classified the meningiomas into groups A, B and C, which corresponded to the three grades except for 3 benign meningiomas with higher proliferation indexes and/or recurrence, included in the atypical group.
  • In the benign tumours, we identified genes with signatures specific for fibroblastic meningiomas (FBLN1, Tenascin C and MMP2 encoding extracellular matrix proteins) and for meningothelial meningiomas (MLPH, DEFB1 and FAT3), suggesting different mechanisms involved in the tumorigenesis of these subtypes.
  • This microarray-based expression profiling study revealed candidate genes and pathways that may contribute to a better understanding of the recurrence of a benign meningioma.
  • Our results might make it possible to determine which benign meningiomas might recur despite complete resection, and will provide helpful information for neurosurgeons in the follow-up of the patients.
  • [MeSH-major] Gene Expression Profiling. Meningeal Neoplasms / genetics. Meningeal Neoplasms / pathology. Meningioma / genetics. Meningioma / pathology


87. Pfister C, Ritz R, Pfrommer H, Bornemann A, Tatagiba MS, Roser F: Are there attacking points in the eicosanoid cascade for chemotherapeutic options in benign meningiomas? Neurosurg Focus; 2007;23(4):E8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are there attacking points in the eicosanoid cascade for chemotherapeutic options in benign meningiomas?
  • OBJECT: The current treatment for recurrent or malignant meningiomas with adjuvant therapies has not been satisfactory, and there is an intense interest in evaluating new molecular markers to act as therapeutic targets.
  • Enzymes of the arachidonic acid (AA) cascade such as cyclooxygenase (COX)-2 or 5-lipoxygenase (5-LO) are upregulated in a number of epithelial tumors, but to date there are hardly any data about the expression of these markers in meningiomas.
  • To find possible targets for chemotherapeutic intervention, the authors evaluated the expression of AA derivatives at different molecular levels in meningiomas.
  • METHODS: One hundred and twenty-four meningioma surgical specimens and normal human cortical tissue samples were immunohistochemically and cytochemically stained for COX-2, COX-1, 5-LO, and prostaglandin E receptor 4 (PTGER4).
  • RESULTS: Sixty (63%) of 95 benign meningiomas, 21 (88%) of 24 atypical meningiomas, all five malignant meningiomas, and all normal human cortex samples displayed high COX-2 immunoreactivity.
  • The PCR analysis demonstrated no changes in eicosanoid expression among meningiomas of different World Health Organization grades and in normal human cortical and dura mater tissue.
  • CONCLUSIONS: Eicosanoid derivatives COX-1, COX-2, 5-LO, and PTGER4 enzymes show a high universal expression in meningiomas but are not upregulated in normal human cortex and dura tissue.
  • This finding of the ubiquitous presence of these enzymes in meningiomas offers an excellent baseline for testing upcoming chemotherapeutic treatments.
  • [MeSH-major] Eicosanoids / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961045.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Eicosanoids; 0 / PTGER4 protein, human; 0 / RNA, Messenger; 0 / Receptors, Prostaglandin E; 0 / Receptors, Prostaglandin E, EP4 Subtype; EC 1.13.11.34 / Arachidonate 5-Lipoxygenase; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  •  go-up   go-down


88. Aghi M, Barker FG 2nd: Benign adult brain tumors: an evidence-based medicine review. Prog Neurol Surg; 2006;19:80-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign adult brain tumors: an evidence-based medicine review.
  • BACKGROUND: Benign adult brain tumors can be managed conservatively or using surgery, radiation, or medicines.
  • METHODS: Review of the literature on benign adult brain tumors using evidence-based standards and focusing on meningiomas, pituitary adenomas, and vestibular schwannomas, which together represent the majority of WHO grade 1 adult brain tumors.
  • RESULTS: Nearly all studies of benign adult brain tumors were of relatively poor quality (level 3 or poorer).
  • These studies enable grade C recommendations.
  • The safety of meningioma surgery in the elderly varies with institution, radiosurgery is a reliable alternative to surgery in small to medium-sized meningiomas, and the efficacy of drugs in therapy of meningiomas recurring after surgery is difficult to interpret due to a lack of uniform criteria in the studies.
  • CONCLUSIONS: While randomized clinical trials comparing conservative management, surgery, radiation, and medical management of benign adult benign tumors are unlikely to occur, there is some level 3 evidence that can assist in their treatment.
  • [MeSH-minor] Adenoma / therapy. Adult. Humans. Meningeal Neoplasms / therapy. Meningioma / therapy. Neuroma, Acoustic / therapy. Neurosurgical Procedures. Phototherapy. Pituitary Neoplasms / therapy. Radiosurgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17033148.001).
  • [ISSN] 0079-6492
  • [Journal-full-title] Progress in neurological surgery
  • [ISO-abbreviation] Prog Neurol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 58
  •  go-up   go-down


89. Martinez-Glez V, Franco-Hernandez C, Alvarez L, De Campos JM, Isla A, Vaquero J, Lassaletta L, Casartelli C, Rey JA: Meningiomas and schwannomas: molecular subgroup classification found by expression arrays. Int J Oncol; 2009 Feb;34(2):493-504
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningiomas and schwannomas: molecular subgroup classification found by expression arrays.
  • As the molecular pathogenesis of meningiomas and schwannomas, characterized by NF2 gene alterations, remains unclear and suitable molecular targets need to be identified, we used low density cDNA microarrays to establish expression patterns of 96 cancer-related genes on 23 schwannomas, 42 meningiomas and 3 normal cerebral meninges.
  • Results showed a high frequency of NF2 gene mutations (40%), increased 22q LOH as aggressiveness increased, frequent losses and gains by MLPA in benign meningiomas, and gene expression silencing by hypermethylation.
  • Array analysis showed decreased expression of 7 genes in meningiomas.
  • Unsupervised analyses identified 2 molecular subgroups for both meningiomas and schwannomas showing 38 and 20 differentially expressed genes, respectively, and 19 genes differentially expressed between the two tumor types.
  • These findings provide a molecular subgroup classification for meningiomas and schwannomas with possible implications for clinical practice.
  • [MeSH-major] Meningeal Neoplasms / genetics. Meningioma / genetics. Neurilemmoma / genetics. Oligonucleotide Array Sequence Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19148485.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / DNA, Neoplasm
  •  go-up   go-down


90. Shirai W, Tokumitsu N, Sako K, Takahashi T: [Hemangiopericytoma at the transverse sinus presenting with intracerebral hemorrhage: case report]. No Shinkei Geka; 2005 Sep;33(9):895-900
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Based on the findings shown in this case report, hemangiopericytoma should be included in the differential diagnosis from benign meningioma.

  • Genetic Alliance. consumer health - Hemangiopericytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16164186.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


91. Liu RS, Chang CP, Guo WY, Pan DH, Ho DM, Chang CW, Yang BH, Wu LC, Yeh SH: 1-11C-acetate versus 18F-FDG PET in detection of meningioma and monitoring the effect of gamma-knife radiosurgery. J Nucl Med; 2010 Jun;51(6):883-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 1-11C-acetate versus 18F-FDG PET in detection of meningioma and monitoring the effect of gamma-knife radiosurgery.
  • This study aimed to define the potential of 1-(11)C-acetate PET, compared with (18)F-FDG, in detecting meningiomas and monitoring the effect of gamma-knife radiosurgery.
  • METHODS: Twenty-two patients with the neuroradiologic diagnosis of meningioma were examined by 1-(11)C-acetate and (18)F-FDG PET on the same day.
  • There were 12 cases of histopathologically proven meningioma (8 grade I, 2 grade II, and 2 grade III), 1 of tuberculous granuloma, and 1 of degenerative tissue.
  • RESULTS: The (18)F-FDG PET study revealed a hypometabolic focus in 17 meningiomas (8 grade I, 1 grade II, and 8 unknown grade) and hypermetabolism in 1 grade II and 2 grade III meningiomas.
  • High uptake of 1-(11)C-acetate was observed in all 20 meningiomas, in contrast to the low uptake in surrounding normal brain tissue, allowing a clearer demarcation of the tumor boundary than that provided by (18)F-FDG.
  • The standardized uptake value for 1-(11)C-acetate was not different from that for (18)F-FDG (mean +/- SD, 3.16 +/- 1.75 vs. 3.22 +/- 1.50, P = 0.601), but the tumor-to-cortex ratio for 1-(11)C-acetate was higher than that for (18)F-FDG (3.46 +/- 1.38 vs. 0.93 +/- 1.08, P < 0.005). (18)F-FDG was able to differentiate grade I from grade II-III meningiomas, whereas 1-(11)C-acetate was unable to do so.
  • Tuberculous granuloma had a high 1-(11)C-acetate and (18)F-FDG uptake similar to that of grade II/III meningioma.
  • CONCLUSION: 1-(11)C-acetate was found to be useful for detecting meningiomas and evaluating the extent of meningiomas and potentially useful for monitoring tumor response to radiosurgery.
  • However, 1-(11)C-acetate was not useful for evaluating the tumor grade. (18)F-FDG was found to be less useful than 1-(11)C-acetate for evaluating the extent of meningiomas and the response to radiosurgical treatment but may be useful for differentiating benign from malignant meningiomas. (18)F-FDG and 1-(11)C-acetate are complementary for assessing diverse cell metabolism of meningioma.
  • [MeSH-major] Acetates. Carbon. Fluorodeoxyglucose F18. Meningioma / radionuclide imaging. Meningioma / surgery. Positron-Emission Tomography / methods. Radiosurgery

  • Genetic Alliance. consumer health - Meningioma.
  • Hazardous Substances Data Bank. CARBON .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20484430.001).
  • [ISSN] 1535-5667
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acetates; 0 / carbon-11 acetate; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 7440-44-0 / Carbon
  •  go-up   go-down


92. Zeidman LA, Ankenbrandt WJ, Du H, Paleologos N, Vick NA: Growth rate of non-operated meningiomas. J Neurol; 2008 Jun;255(6):891-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth rate of non-operated meningiomas.
  • INTRODUCTION: Meningiomas are dural-based brain tumors that are typically histologically benign.
  • Some meningiomas grow slowly or seemingly not at all with planimetric measurement.
  • Two meningiomas (9.09 %) demonstrated no growth.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningeal Neoplasms / physiopathology. Meninges / pathology. Meninges / physiopathology. Meningioma / pathology. Meningioma / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2000 May;92(5):766-70 [10794289.001]
  • [Cites] J Neurosurg. 1995 Aug;83(2):222-4 [7616265.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(5):507-11 [10898357.001]
  • [Cites] Neurology. 2004 Sep 28;63(6):1133-4 [15452322.001]
  • [Cites] Neurosurgery. 2003 Jul;53(1):62-70; discussion 70-1 [12823874.001]
  • [Cites] J Neurosurg. 1990 Oct;73(4):545-7 [2398385.001]
  • [Cites] Neurology. 1997 May;48(5):1459-62 [9153494.001]
  • [Cites] Neurology. 1998 Dec;51(6):1718-20 [9855530.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2000 Jan;68(1):25-8 [10601396.001]
  • [Cites] Stroke. 1996 Aug;27(8):1304-5 [8711791.001]
  • (PMID = 18350353.001).
  • [ISSN] 0340-5354
  • [Journal-full-title] Journal of neurology
  • [ISO-abbreviation] J. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


93. Johnson WD, Loredo LN, Slater JD: Surgery and radiotherapy: complementary tools in the management of benign intracranial tumors. Neurosurg Focus; 2008;24(5):E2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery and radiotherapy: complementary tools in the management of benign intracranial tumors.
  • As more modern capabilities are employed in surgery and radiotherapy, attention is being directed to the utility of radiation as either primary or secondary treatment of benign tumors.
  • Specifically, primary treatment encompasses irradiation of small benign tumors without biopsy confirmation of tumor type; secondary treatment involves postoperative radiation therapy, with the possibility that less-aggressive tumor resection may be performed in areas that have a higher probability of resultant neurological deficit.
  • Current literature suggests that this is not only a possible treatment strategy, but that it may be superior to more radical resection in some cases, for example, in vestibular schwannomas and meningiomas.
  • This article provides an overview of factors to consider in the use of radiation therapy and reviews the relationships between radiation and surgery, notably the unique complementary role each plays in the treatment of benign intracranial tumors.
  • [MeSH-minor] Adenoma / radiotherapy. Adenoma / surgery. Combined Modality Therapy. Dose Fractionation. Elementary Particles / therapeutic use. Humans. Meningeal Neoplasms / radiotherapy. Meningeal Neoplasms / surgery. Meningioma / radiotherapy. Meningioma / surgery. Neurilemmoma / radiotherapy. Neurilemmoma / ultrasonography. Pituitary Neoplasms / radiotherapy. Pituitary Neoplasms / surgery. Radioisotopes / therapeutic use. Radiosurgery / instrumentation. Radiosurgery / methods. Radiotherapy, Computer-Assisted / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18447741.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radioisotopes
  • [Number-of-references] 55
  •  go-up   go-down


94. Kollová A, Liscák R, Novotný J Jr, Vladyka V, Simonová G, Janousková L: Gamma Knife surgery for benign meningioma. J Neurosurg; 2007 Aug;107(2):325-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma Knife surgery for benign meningioma.
  • OBJECT: Meningioma is the most frequent benign tumor treated with Gamma Knife surgery (GKS); however, the assessment of its efficacy and safety in slow-growing tumors is an ongoing process, requiring analysis of long-term results.
  • METHODS: Three hundred sixty-eight patients harboring 400 meningiomas treated between 1992 and 1999 at Na Homolce Hospital were evaluated.
  • CONCLUSIONS: Stereotactic radiosurgery is a safe method of treatment for meningiomas.
  • A minimum margin dose of 12 to 16 Gy seems to represent the therapeutic window for benign meningiomas with a high tumor control rate in a mid-term follow-up period.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / pathology. Meningioma / surgery. Radiosurgery

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17695387.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Llauger J, Aixut S, Cañete N, Palmer J, Solà M, Bagué S: Meningioma of the scapula. Skeletal Radiol; 2008 Feb;37(2):169-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningioma of the scapula.
  • Meningiomas account for approximately 15% of all intracranial tumors and are the most common non-glial primary tumors of the central nervous system.
  • Most meningiomas are benign neoplasms with characteristic imaging features.
  • Primary extradural meningiomas account for only 1-2% of all meningiomas.
  • They must be differentiated from intradural meningiomas with secondary extradural extension and/or metastases.
  • The vast majority of extradural meningiomas are found in the skull or in the head and neck region.
  • We report on an extremely rare case of primary extradural meningioma that was located in the scapula.
  • To the best of our knowledge, this form of presentation of an extradural meningioma has not been previously described.
  • [MeSH-major] Bone Neoplasms / diagnosis. Meningioma / diagnosis. Scapula / diagnostic imaging. Scapula / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 2005 Sep;26(8):2053-6 [16155159.001]
  • [Cites] J Neurosurg. 2000 Dec;93(6):940-50 [11117866.001]
  • [Cites] Jpn J Clin Oncol. 2000 Jul;30(7):313-7 [11007165.001]
  • [Cites] Am J Surg Pathol. 1996 Apr;20(4):492-9 [8604818.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Aug;18(7):1335-7 [9282866.001]
  • [Cites] Hum Pathol. 1991 May;22(5):469-74 [1709609.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):453-60 [9130993.001]
  • [Cites] Ann Thorac Surg. 2006 May;81(5):1903-4 [16631706.001]
  • [Cites] Skeletal Radiol. 2001 Nov;30(11):639-42 [11810156.001]
  • (PMID = 18030466.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


96. Rodriguez FJ, Scheithauer BW, Roncaroli F, Silva AI, Kovacs K, Brat DJ, Jin L: Galectin-3 expression is ubiquitous in tumors of the sellar region, nervous system, and mimics: an immunohistochemical and RT-PCR study. Am J Surg Pathol; 2008 Sep;32(9):1344-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Galectin-3 expression has been reported in spindle cell oncocytoma, certain pituitary adenoma subtypes, astrocytomas, oligodendrogliomas, and meningiomas.
  • Significant differences in protein expression were noted in the following 2 settings: specific meningioma subtypes (P=0.004, Fisher exact test) wherein clear cell meningioma demonstrated weak protein expression when compared with other meningioma variants.
  • No significant difference was noted with respect to World Health Organization grade.
  • Galectin-3 was also strongly expressed in benign nerve sheath tumors but only moderately expressed in malignant peripheral nerve sheath tumors (P=0.0009, Fisher exact test).
  • Although galectin-3 positivity is a key feature of the immunophenotype of spindle cell oncocytoma, its consistent expression in other morphologically similar tumors (meningioma, pituicytoma, nerve sheath tumors, granular cell tumor, metastases) makes it of little use in the differential diagnosis of sellar region tumors, a setting in which it should be discouraged.
  • Diagnostic uses of this marker may be limited to specific settings, including some meningioma subtypes and nerve sheath tumors.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18670355.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3
  •  go-up   go-down


97. Slavik E, Radulović D, Tasić G: Olfactory groove meningiomas. Acta Chir Iugosl; 2007;54(2):59-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Olfactory groove meningiomas.
  • Meningiomas, usually histologically benign tumors, are originating from the arachnoidal cap cells normally present intracranially in varying sites.
  • This series is consisted of 29 patients suffering from olfactory groove meningiomas treated surgicaly between May 1992 and November 2003.
  • [MeSH-major] Meningeal Neoplasms. Meningioma

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18044317.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


98. De Verdelhan O, Haegelen C, Carsin-Nicol B, Riffaud L, Amlashi SF, Brassier G, Carsin M, Morandi X: MR imaging features of spinal schwannomas and meningiomas. J Neuroradiol; 2005 Jan;32(1):42-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MR imaging features of spinal schwannomas and meningiomas.
  • Spinal schwannomas and meningiomas are mostly benign, intra-dural extramedullary tumours.
  • We retrospectively reviewed the Magnetic Resonance Imaging (MRI) examinations of 52 spinal schwannomas and meningiomas operated on at our institution since 1998.
  • The series included 28 schwannomas and 24 meningiomas.
  • We compared MRI features of schwannomas and meningiomas and evaluated statistical features that would allow differentiation.
  • Concerning the cranio-caudal distribution, half of the cervical tumours were schwannomas, 72% of thoracic lesions were meningiomas and all lumbar tumours were schwannomas.
  • Meningiomas were significantly located at the upper and mid thoracic levels and schwannomas in the lumbar area.
  • On T1-weighted images, MRI signal intensity and heterogeneity were not statistically different between meningiomas and schwannomas.
  • After Gd-DTPA, we observed a significant difference between meningiomas and schwannomas, the enhancement being intense and heterogeneous in cases of schwannomas, and moderate and homogeneous in cases of meningiomas.
  • It was found in only 16 cases of meningiomas.
  • In conclusion, we consider that a diagnosis of schwannoma should be made when a spinal intradural extramedullary tumour shows hyperintensity on T2W images or intense enhancement without dural tail sign; otherwise meningioma is more probable.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Meningioma / diagnosis. Neurilemmoma / diagnosis. Spinal Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15798613.001).
  • [ISSN] 0150-9861
  • [Journal-full-title] Journal of neuroradiology. Journal de neuroradiologie
  • [ISO-abbreviation] J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


99. Ong L, Ferrucci S: Tuberculum sellae meningioma associated with lymphomatoid papulosis. Optometry; 2005 Mar;76(3):165-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tuberculum sellae meningioma associated with lymphomatoid papulosis.
  • BACKGROUND: Meningiomas involving the tuberculum sellae and planum sphenoidale typically cause visual loss by affecting the optic nerve and anterior chiasm.
  • We present a case of a tuberculum sellae meningioma concurrent with lymphomatoid papulosis, a T-cell lymphomatoid skin disorder.
  • MRI revealed a meningioma arising from the tuberculum sellae and planum sphenoidale region.
  • The meningioma was partially resected nine days later Visual field performed 18 days postoperatively demonstrated an overall depression in the right eye and no defect in the left eye.
  • CONCLUSION: Meningiomas are generally benign tumors that can cause symptoms if vital structures are compromised.
  • Intracranial meningiomas may be associated with systemic conditions that can infiltrate the optic nerve, including lymphocytic disorders.
  • It is unclear if there is a direct association between LyP and meningiomas.
  • [MeSH-major] Lymphomatoid Papulosis / complications. Meningeal Neoplasms / complications. Meningioma / complications. Optic Atrophy / etiology. Sella Turcica / pathology. Vision Disorders / etiology


100. Tabernero MD, Maillo A, Gil-Bellosta CJ, Castrillo A, Sousa P, Merino M, Orfao A: Gene expression profiles of meningiomas are associated with tumor cytogenetics and patient outcome. Brain Pathol; 2009 Jul;19(3):409-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiles of meningiomas are associated with tumor cytogenetics and patient outcome.
  • Cytogenetic analysis is a powerful tool for predicting recurrence in meningiomas, even among histologically benign/grade I tumors.
  • Despite this, no study has been reported in which the impact of tumor cytogenetics on the gene expression profiles (GEP) has been analyzed in meningiomas.
  • Here, we analyzed the GEP of 47 tumors and correlated them with the most clinical relevant cytogenetic subgroups of meningiomas, as confirmed through the analysis of 172 patients.
  • Overall, our results show a clear association between the clinically relevant cytogenetic subgroups of meningiomas including diploid tumors (n = 18), isolated -22/22q- (n = 12), del(1p36) alone (n = 4) and complex karyotypes associated with del(1p36) and/or -14q (n = 13) and their GEP.
  • In summary, we show a clear association between GEP of neoplastic cells and clinically relevant cytogenetic subgroups of meningiomas.
  • [MeSH-major] Cytogenetic Analysis. Gene Expression Profiling. Meningeal Neoplasms / genetics. Meningioma / genetics. Neoplasm Recurrence, Local / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18637901.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down






Advertisement